References

2024 Non Cancer PAIN

References

2024 NON CANCER PAIN

  1. Onofrio BM, Yaksh TL, Arnold PG. Continuous low-dose intrathecal morphine administration in the treatment of chronic pain of malignant origin. Mayo Clin Proc. 1981;56:516–520.
  2. Follett KA, Hitchon PW, Piper J, Kumar V, Clamon G, Jones MP. Response of intractable pain to continuous intrathecal morphine: a retrospective study. Pain. 1992;49:21–25.
  3. Winkelmüller M, Winkelmüller W. Long-term effects of continuous intrathecal opioid treatment in chronic pain of nonmalignant etiology. J Neurosurg. 1996;85:458–467.
  4. Bennett G, Burchiel K, Buchser E, et al. Clinical guidelines for intraspinal infusion: report of an expert panel. PolyAnalgesic Consensus Conference 2000. J Pain Symptom Manage. 2000;20:S37–S43.
  5. Deer T, Krames ES, Hassenbusch SJ, et al. Polyanalgesic consensus conference 2007: recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation. 2007;10:300–328.
  6. Deer TR, Prager J, Levy R, et al. Polyanalgesic Consensus Conference 2012: recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation. 2012;15:436–464 [discussion: 464–436].
  7. Deer TR, Prager J, Levy R, et al. Polyanalgesic Consensus Conference–2012: recommendations on trialing for intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation. 2012;15:420–435 [discussion: 435].
  8. Deer TR, Prager J, Levy R, et al. Polyanalgesic Consensus Conference–2012: consensus on diagnosis, detection, and treatment of catheter-tip granulomas (inflammatory masses). Neuromodulation. 2012;15:483–495 [discussion 496].
  9. Deer TR, Levy R, Prager J, et al. Polyanalgesic Consensus Conference–2012: recommendations to reduce morbidity and mortality in intrathecal drug delivery in the treatment of chronic pain. Neuromodulation. 2012;15:467–482 [discussion 482].
  10. Deer TR, Pope JE, Hayek SM, et al. The Polyanalgesic Consensus Conference (PACC®) recommendations on intrathecal drug infusion systems best practices and guidelines. Neuromodulation. 2017;20:96 – 132.
  11. Deer TR, Hayek SM, Pope JE, et al. The Polyanalgesic Consensus Conference (PACC®) recommendations for trialing of intrathecal drug delivery infusion therapy. Neuromodulation. 2017;20:133–154.
  12. Deer TR, Pope JE, Hayek SM, et al. The Polyanalgesic Consensus Conference (PACC®) recommendations for intrathecal drug delivery for improving safety and mitigating risk. Neuromodulation. 2017;20:155–176.
  13. Silverman E. Everything you need to know about the Sunshine Act. BMJ. 2013;347, f4704.
  14. Harris RP, Helfand M, Woolf SH, et al. Third U.S. Preventive Services Task Force. a review of the process. Am J Prev Med. 2001;20:21–35.
  15. Doleys DM. Pain: Dynamics and Complexities. Oxford University Press; 2014.
  16. Block AR, Darwer DB. Presurgical Psychological Screening: Understanding Patients. Improving Outcomes. American Psychological Association Books; 2013.
  17. Bendinger T, Plunkett N, Poole D, Turnbull D. Psychological factors as outcome predictors for spinal cord stimulation. Neuromodulation. 2015;18:465–471 [discussion 471].
  18. Sparkes E, Duarte RV, Mann S, Lawrence TR, Raphael JH. Analysis of psychological characteristics impacting spinal cord stimulation treatment outcomes: a prospective assessment. Pain Phys. 2015;18:E369–E377.
  19. Robb LP, Cooney JM, McCrory CR. Evaluation of spinal cord stimulation on the symptoms of anxiety and depression and pain intensity in patients with failed back surgery syndrome. Ir J Med Sci. 2017;186:767–771.
  20. Fama CA, Chen N, Prusik J, et al. The use of preoperative psychological evaluations to predict spinal cord stimulation success: our experience and a review of the literature. Neuromodulation. 2016;19:429–436.
  21. Maatta J, Martikainen A, Pakarinen M, et al. High level of childhood trauma predicts a poor response to spinal cord stimulation in chronic neuropathic pain. Pain Phys. 2019;22:E37–E44.
  22. Sheldon BL, Khazen O, Feustel PJ, et al. Correlations between family history of psychiatric illnesses and outcomes of spinal cord stimulation. Neuromodulation. 2020;23:667–672.
  23. Prabhala T, Kumar V, Gruenthal E, et al. Use of a psychological evaluation tool as a predictor of spinal cord stimulation outcomes. Neuromodulation. 2019;22:194– 199.
  24. Grinberg AM, D’Eon MS, Ellison JK, Rutledge T, Castellanos J, Chakravarthy KV. A revised psychosocial assessment model for implantable pain devices to improve their evidence basis and consensus with updated pain management Pain Management 2019;9:139–149.
  25. Thomson S, Huygen F, Prangnell S, et al. Appropriate referral and selection of patients with chronic pain for spinal cord stimulation: European consensus recommendations and e-health tool. Eur J Pain. 2020;24:1169–1181.
  26. Kim P, Deer T. Managing intrathecal drug delivery devices in a global pandemic. Neuromodulation. 2020;23:716–717.
  27. Perez J, Niburski K, Stoopler M, Ingelmo P. Telehealth and chronic pain management from rapid adaptation to long-term implementation in pain medicine: a narrative review. PAIN Rep. 2021;6:e912.
  28. Chou R, Turner JA, Devine EB, et al. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med. 2015;162:276–286.
  29. Gery P, Guy Jr , Zhang Kun, Bohm Michele K, et al. Vital Signs: changes in opioid prescribing in the United States, 2006–2015. Morbidity and Mortality Weekly Report. 2017;66:697–704.
  30. Vital Signs: Overdoses of prescription opioid pain relievers—United States, 1999 – MMWR. Morbidity and Mortality Wkly Report. 2011;60:1487–1492.
  31. Eccleston C, Fisher E, Thomas KH, et al. Interventions for the reduction of prescribed opioid use in chronic non-cancer pain. Cochrane Database Syst Rev. 2017;11, CD010323.
  32. Fishbain DA, Pulikal A. Does opioid tapering in chronic pain patients result in improved pain or same pain vs increased pain at taper completion? a structured evidence-based systematic review. Pain Med. 2019;20:2179–2197.
  33. Frank JW, Lovejoy TI, Becker WC, et al. Patient outcomes in dose reduction or discontinuation of long-term opioid therapy: a systematic review. Ann Intern Med. 2017;167:181–191.
  34. Sandhu H, Underwood M, Furlan AD, Noyes J, Eldabe S. What interventions are effective to taper opioids in patients with chronic pain? BMJ. 2018;362:k2990.
  35. Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC clinical practice guideline for prescribing opioids for pain — United States, 2022. MMWR Recomm Rep. 2022;71:1–95.
  36. Sandhu HK, Abraham C, Alleyne S, et al. Testing a support programme for opioid reduction for people with chronic non-malignant pain: the I-WOTCH randomized controlled trial protocol. BMJ Open. 2019;9, e028937.
  37. Darnall BD, Mackey SC, Lorig K, et al. Comparative effectiveness of cognitive behavioral therapy for chronic pain and chronic pain self-management within the context of voluntary patient-centered prescription opioid tapering: the EMPOWER Study Protocol. Pain Med. 2020;21:1523–1531.
  38. Darnall BD, Roy A, Chen AL, et al. Comparison of a single-session pain management skills intervention with a single-session health education intervention and 8 sessions of cognitive behavioral therapy in adults with chronic low back pain: a randomized clinical trial. JAMA Netw Open. 2021;4, e2113401.
  39. Hill R, Duarte R, Eldabe S, et al. Safe and effective gradual reduction (tapering) of opioids in people with chronic non-cancer pain: systematic review of effects, barriers and facilitators and inequalities to inform service design in the NHS.
  40. Abd-Elsayed A, Karri J, Michael A, et al. Intrathecal drug delivery for chronic pain syndromes: a review of considerations in practice management. Pain Phys. 2020;23:E591–E617.
  41. Abd-Sayed A, Fiala K, Weisbein J, et al. Intrathecal Drug Delivery Systems Survey: trends in utilization in pain practice. J Pain Res. 2022;15:1305–1314.
  42. Karri J, Singh M, Modi DJ, et al. Combination intrathecal drug therapy strategies for pain management. Pain Phys. 2021;24:549–569.
  43. Guay DR. Adjunctive agents in the management of chronic pain. Pharmacotherapy. 2001;21:1070–1081.
  44. Wallace M, Webster L, Rauck R, et al. Effect of concomitant antidepressant and anticonvulsant use on adverse events in patients receiving intrathecal ziconotide in a long-term extension study. J Pain. 2014;15S74: abstract #393.
  45. Bair MJ, Robinson RL, Katon W, Kroenke K. Depression and pain comorbidity: a literature review. Arch Intern Med. 2003;163:2433–2445.
  46. Rayner L, Hotopf M, Petkova H, Matcham F, Simpson A, McCracken LM. Depression in patients with chronic pain attending specialized pain treatment center: prevalence and impact on health care costs. Pain. 2016;157:1472–1479.
  47. Deer T, Chapple I, Classen A, et al. Intrathecal drug delivery for treatment of chronic low back pain: report from the National Outcomes Registry for Low BackPain Med. 2004;5:6 –13.
  48. Feinberg SD, Gatchel RJ, Stanos S, Feinberg R, Johnson – Montieth V. Interdisciplinary functional restoration and pain programs. In: Deer TR, Leong MS, Ray AL, eds. Treatment of Chronic Pain by Integrative Approaches. Springer; 2014:169 –182.
  49. LaRowe LR, Ditre JW. Pain, nicotine, and tobacco smoking: current state of the Pain. 2020;161:1688 –1693.
  50. De Gregori M, Muscoli C, Schatman ME, et al. Combining pain therapy with lifestyle: the role of personalized nutrition and nutritional supplements according to the SIMPAR Feed Your Destiny approach. J Pain Res. 2016;9:1179 –1189.
  51. Narouze S, Souzdalnitski D. Obesity and chronic pain: systematic review of prevalence and implications for pain practice. Reg Anesth Pain Med. 2015;40:91.
  52. Stokes A, Lundberg DJ, Hempstead K, Berry KM, Baker JF, Preston SH. Obesity and incident prescription opioid use in the U.S., 2000–2015. Am J Prev Med. 2020;58:766 – 775.
  53. US FDA. Use Caution with Implanted Pumps for Intrathecal Administration of Medicines for Pain Management: FDA Safety Communication. November 14, 2018:2 – 5.
  54. Deer T, Kim P, Pope JE, et al. Physician guidance on the use of off-labeled drugs in intrathecal drug delivery systems for chronic pain. Neuromodulation. 2019;22:765 – 768.
  55. Konrad PE, Huffman JM, Stearns LM, et al. Intrathecal drug delivery systems (IDDS): the implantable systems performance registry (ISPR). Neuromodulation. 2016;19:848 – 856.
  56. Prager J, Deer T, Levy R, et al. Best practices for intrathecal drug delivery for pain. Neuromodulation. 2014;17:354 – 372 [discussion 372].
  57. US Pharmacopeia. Chapter 797. Accessed August 4, 2023.
  58. Copley S, Yassa PE, Batterham AM, et al. A clinical evaluation of the accuracy of an intrathecal drug delivery device. Neuromodulation. 2023;26:1240 – 1246.
  59. Hamza M, Doleys DM, Saleh, Medvedovsky A, Verdolin MH, Hamza MA. Prospective, randomized, single-blinded, head-to-head long-term outcome study comparing intrathecal boluses with continuous infusion trialing techniques prior to implantation of drug delivery systems for the treatment of severe intractable chronic nonmalignant pain. Neuromodulation. 2015;18:636 – 648 [discussion 649].
  60. Bernards CM. Cerebrospinal fluid and spinal cord distribution of Baclofen and bupivacaine during slow intrathecal infusion in pigs. Anesthesiology. 2006;105:169 – 178.
  61. Yaksh TL, Fisher CJ, Hockman TM, Wiese AJ. Current and future issues in the development of spinal agents for the management of pain. Curr Neuropharmacol. 2017;15:232 – 259.
  62. Hsu Y, Hettiarachchi HD, Zhu DC, Linninger AA. The frequency and magnitude of cerebrospinal fluid pulsations influence intrathecal drug distribution: key factors for interpatient variability. Anesth Analg. 2012;115:386–394.
  63. Pharmacology of intrathecally administered agents for treatment of spasticity and pain. In: Hayek SM, Joseph PN, Mekhail NA, eds. Seminars in Pain Medicine. Elsevier; 2003.
  64. Kroin JS, Ali A, York M, Penn RD. The distribution of medication along the spinal canal after chronic intrathecal administration. Neurosurgery. 1993;33:226 – 230 [discussion 30].
  65. Ummenhofer WC, Arends RH, Shen DD, Bernards CM. Comparative spinal distribution and clearance kinetics of intrathecally administered morphine, fentanyl, alfentanil, and sufentanil. Anesthesiology. 2000;92:739 – 753.
  66. Dominguez E, Sahinler B, Bassam D, et al. Predictive value of intrathecal narcotic trials for long-term therapy with implantable drug administration systems in chronic non-cancer pain patients. Pain Pract. 2002;2:315 – 325.
  67. Bernards CM. Understanding the physiology and pharmacology of epidural and intrathecal opioids. Best Pract Res Clin Anaesthesiol. 2002;16:489 – 505.
  68. Bernards CM. Recent insights into the pharmacokinetics of spinal opioids and the relevance to opioid selection. Curr Opin Anaesthesiol. 2004;17:441 – 447.
  69. Sandler AN, Stringer D, Panos L, et al. A randomized, double-blind comparison of lumbar epidural and intravenous fentanyl infusions for postthoracotomy pain Analgesic, pharmacokinetic, and respiratory effects. Anesthesiology. 1992;77:626 – 634.
  70. Ade T, Roh J, Sharma G, et al. Comparative effectiveness of targeted intrathecal drug delivery using a combination of bupivacaine with either low-dose fentanyl or hydromorphone in chronic back pain patients with lumbar postlaminectomy Pain Med. 2020;21:1921 – 1928.
  71. Galica RJ, Hayek SM, Veizi E, et al. Intrathecal trialing of continuous infusion combination therapy with hydromorphone and bupivacaine in failed back surgery patients. Neuromodulation. 2018;21:648 – 654.
  72. Hayek SM, Jones BA, Veizi E, Tran TQ, DeLozier SJ. Efficacy of continuous intrathecal infusion trialing with a mixture of fentanyl and bupivacaine in chronic low back pain patients. Pain Med. 2023;24:796 – 808.
  73. Burton AW, Deer TR, Wallace MS, Rauck RL, Grigsby E. Considerations and methodology for trialing ziconotide. Pain Phys. 2010;13:23 – 33.
  74. Ver Donck A, Collins R, Rauck RL, Nitescu P. An open-label, multicenter study of the safety and efficacy of intrathecal ziconotide for severe chronic pain when delivered via an external pump. Neuromodulation. 2008;11:103 – 111.
  75. Mohammed SI, Eldabe S, Simpson KH, et al. Bolus intrathecal injection of ziconotide (Prialt(R)) to evaluate the option of continuous administration via an implanted intrathecal drug delivery (ITDD) system: a pilot study. Neuromodulation. 2013;16:576 – 581 [discussion 582].
  76. Bäckryd E, Sörensen J, Gerdle B. Ziconotide trialing by intrathecal bolus injections: an open-label non-randomized clinical trial in postoperative/posttraumatic neuropathic pain patients refractory to conventional treatment. Neuromodulation. 2015;18:404 – 413.
  77. Hayek SM, Hanes MC, Wang C, Veizi IE. Ziconotide combination intrathecal therapy for noncancer pain is limited secondary to delayed adverse effects: a case series with a 24-month follow-up. Neuromodulation. 2015;18:397 – 403.
  78. Pope JE, Deer TR. Intrathecal pharmacology update: novel dosing strategy for intrathecal monotherapy ziconotide on efficacy and sustainability. Neuromodulation. 2015;18:414 – 420.
  79. Deer T, Rauck RL, Kim P, et al. Effectiveness and safety of intrathecal ziconotide: interim analysis of the Patient Registry of Intrathecal Ziconotide Management (PRIZM). Pain Pract. 2018;18:230 – 238.
  80. Henry-Feugeas MC, Idy-Peretti I, Baledent O, et al. Origin of subarachnoid cerebrospinal fluid pulsations: a phase-contrast MR analysis. Magn Reson Imaging. 2000;18:387 – 395.
  81. Daouk J, Bouzerar R, Baledent O. Heart rate and respiration influence on macroscopic blood and CSF flows. Acta Radiol. 2017;58:977 – 982.
  82. Brogan SE, Odell DW, Sindt JE, et al. Dorsal versus ventral intrathecal catheter tip location and effect on dose escalation and opioid use in patients with cancer pain. Neuromodulation. 2023;26:1233 – 1239.
  83. Urits I, Petro J, Viswanath O, Aner M. Retrograde placement of an intrathecal catheter for chronic low pelvic cancer pain. J Clin Anesth. 2019;54:43 – 44.
  84. Hayek SM, Sweet JA, Miller JP, Sayegh RR. Successful management of corneal neuropathic pain with intrathecal targeted drug delivery. Pain Med. 2016;17:1302 – 1307.
  85. Moman RN, Rogers JM, Pittelkow TP. High cervical intrathecal targeted drug delivery: a case report of refractory oropharyngeal cancer pain. Case Rep Oncol Med. 2019;2019, 2098921.
  86. Enzmann DR, Pelc NJ. Cerebrospinal fluid flow measured by phase-contrast cine AJNR Am J Neuroradiol. 1993;14:1301–1397 [discussion 1309 – 1310].
  87. Dreha-Kulaczewski S, Joseph AA, Merboldt KD, Ludwig HC, Gärtner J, Frahm J. Inspiration is the major regulator of human CSF flow. J Neurosci. 2015;35:2485.

  88. Stockman HW. Effect of anatomical fine structure on the dispersion of solutes in the spinal subarachnoid space. J Biomech Eng. 2007;129:666 – 675.

  89. Stoquart-ElSankari S, Balédent O, Gondry-Jouet C, Makki M, Godefroy O, Meyer ME. Aging effects on cerebral blood and cerebrospinal fluid flows. J Cereb Blood Flow Metab. 2007;27:1563 – 1572.

  90. Shin BS, Kim CS, Sim WS, et al. A comparison of the effects of preanesthetic administration of crystalloid versus colloid on intrathecal spread of isobaric spinal anesthetics and cerebrospinal fluid movement. Anesth Analg. 2011;112:924–930.

  91. Flack SH, Anderson CM, Bernards C. Morphine distribution in the spinal cord after chronic infusion in pigs. Anesth Analg. 2011;112:460–464.

  92. Flack SH, Bernards CM. Cerebrospinal fluid and spinal cord distribution of hyperbaric bupivacaine and Baclofen during slow intrathecal infusion in pigs. Anesthesiology. 2010;112:165–173.

  93. Hejtmanek MR, Harvey TD, Bernards CM. Measured density and calculated baricity of custom-compounded drugs for chronic intrathecal infusion. Reg Anesth Pain Med. 2011;36:7 – 11.
  94. van der Plas AA, Marinus J, Eldabe S, Buchser E, van Hilten JJ. The lack of efficacy of different infusion rates of intrathecal Baclofen in complex regional pain syndrome: a randomized, double-blind, crossover study. Pain Med. 2011;12:459.
  95. Perruchoud C, Eldabe S, Durrer A, et al. Effects of flow rate modifications on reported analgesia and quality of life in chronic pain patients treated with continuous intrathecal drug therapy. Pain Med. 2011;12:571 – 576.
  96. Eldabe S, Duarte RV, Madzinga G, et al. Comparison of the effects of intermittent boluses to simple continuous infusion on patients’ global perceived effect in intrathecal therapy for pain: A randomized double-blind crossover study. Pain Med. 2017;18:924 – 931.
  97. Hildebrand KR, Page LM, Billstrom TM, et al. Characterization of effect of repeated bolus or continuous intrathecal infusion of morphine on spinal mass formation in the dog. Neuromodulation. 2019;22:790 – 798.
  98. Robinson S, Robertson FC, Dasenbrock HH, O’Brien CP, Berde C, Padua H. Image-guided intrathecal Baclofen pump catheter implantation: a technical note and case series. J Neurosurg Spine. 2017;26:621–627.
  99. Thakur SK, Rubin BA, Harter DH. Long-term follow-up for lumbar intrathecal Baclofen catheters placed using the paraspinal subfascial technique. J Neurosurg Pediatr. 2016;17:357–360.
  100. Devine O, Harborne A, Lo WB, Weinberg D, Ciras M, Price R. Unusual placement of intrathecal Baclofen pumps: report of two cases. Acta Neurochir (Wien). 2016;158:167 – 170.
  101. Narang S, Srinivasan SK, Zinboonyahgoon N, Sampson CE. Upper antero-medial thigh as an alternative site for implantation of intrathecal pumps: a case series. Neuromodulation. 2016;19:655 – 663.
  102. Deer TR, Provenzano DA, Hanes M, et al. The neurostimulation Appropriateness Consensus Committee (NACC®) recommendations for infection prevention and Neuromodulation. 2017;20:31 – 50.
  103. Bakhsheshian J, Dahdaleh NS, Lam SK, Savage JW, Smith ZA. The use of vancomycin powder in modern spine surgery: systematic review and meta-analysis of the clinical evidence. World Neurosurg. 2015;83:816 – 823.

  104. CDC issues recommendations for preventing spread of vancomycin resistance. Am J Health Syst Pharm. 1995;52:1272 – 1274.
  105. Desai VR, Raskin JS, Mohan A, et al. A standardized protocol to reduce pediatric Baclofen pump infections: a quality improvement initiative. J Neurosurg Pediatr. 2018;21:395–400.
  106. Nagel SJ, Frizon L, Maiti T, et al. Contemporary approaches to preventing and treating infections of novel intrathecal neurostimulation devices. World Neurosurg. 2019;128:e397 – e408.
  107. Arocho-Quinones EV, Huang CC, Ward BD, Pahapill PA. Care bundle approach to minimizing infection rates after neurosurgical implants for neuromodulation: a single-surgeon experience. World Neurosurg. 2019;128:e87 – e97.
  108. Scanlon MM, Gazelka HM, Moeschler SM, et al. Surgical site infections in cancer patients with intrathecal drug delivery devices. Pain Med. 2017;18:520 – 525.
  109. Kawata M, Sasabuchi Y, Taketomi S, et al. Atopic dermatitis is a novel demographic risk factor for surgical site infection after anterior cruciate ligament reconstruction. Knee Surg Sports Traumatol Arthrosc. 2018;26:3699 – 3705.
  110. Blood AG, Sandoval MF, Burger E, Halverson-Carpenter K. Risk and protective factors associated with surgical infections among spine patients. Surg Infect (Larchmt). 2017;18:234 – 249.
  111. Boster AL, Adair RL, Gooch JL, et al. Best practices for intrathecal Baclofen therapy: dosing and long-term management. Neuromodulation. 2016;19:623 – 631.
  112. Wilkes D. Programmable intrathecal pumps for the management of chronic pain: recommendations for improved efficiency. J Pain Res. 2014;7:571 – 577.
  113. Coffey RJ, Owens ML, Broste SK, et al. Medical practice perspective: identification and mitigation of risk factors for mortality associated with intrathecal opioids for non-cancer pain. Pain Med. 2010;11:1001 – 1009.
  114. Synchromed Programmable Infusion Systems. Clinical Reference Guide. Medtronic; 2021.
  115. Prometra II. Programmable infusion pump system product information. Flowonix. 2017.
  116. Tangen KM, Leval R, Mehta AI, Linninger AA. Computational and in vitro experimental investigation of intrathecal drug distribution: parametric study of the effect of injection volume, cerebrospinal fluid pulsatility, and drug uptake. Anesth Analg. 2017;124:1686 – 1696.
  117. Artru A. Spinal cerebrospinal fluid chemistry and physiology. In: Spinal Drug Delivery. Elsevier; 1999:177 – 237.
  118. Kuttler A, Dimke T, Kern S, Helmlinger G, Stanski D, Finelli LA. Understanding pharmacokinetics using realistic computational models of fluid dynamics: biosimulation of drug distribution within the CSF space for intrathecal drugs. J Pharmacokinet Pharmacodyn. 2010;37:629 – 644.
  119. Rosen SM, Bromberg TA, Padda G, et al. Intrathecal administration of Infumorph(R) vs compounded morphine for treatment of intractable pain using the Prometra(R) programmable pump. Pain Med. 2013;14:865 – 873.
  120. Hettiarachchi HD, Hsu Y, Harris Jr TJ, Penn R, Linninger AA. The effect of pulsatile flow on intrathecal drug delivery in the spinal canal. Ann Biomed Eng. 2011;39:2592 – 2602.
  121. McDowell G. Use of the personal therapy manager with Prialt (ziconotide intrathecal infusion) for patient controlled analgesia: a case series highlighting techniques and outcomes. Presented at: 14th Annual Meeting of the North American Neuromodulation Society; 2010. Las Vegas, NV.
  122. McDowell 2nd GC, Pope JE. Intrathecal ziconotide: dosing and administration strategies in patients with refractory chronic pain. Neuromodulation. 2016;19:522.
  123. Sindt JE, Odell DW, Tariq R, Presson AP, Zhang C, Brogan SE. Initial intrathecal dose titration and predictors of early dose escalation in patients with cancer using a 100 : 1 oral to intrathecal morphine conversion ratio. Neuromodulation. 2021;24:1157 – 1166.
  124. Hamza M, Doleys D, Wells M, et al. Prospective study of 3-year follow-up of low-dose intrathecal opioids in the management of chronic nonmalignant pain. Pain Med. 2012;13:1304 – 1313.
  125. Ilias W, Todoroff B. Optimizing pain control through the use of implantable Med Devices (Auckl). 2008;1:41 – 47.
  126. Bienfait F, Jubier-Hamon S, Seegers V, et al. First evaluation switching from ropivacaine to highly concentrated bupivacaine in intrathecal mixtures for cancer Neuromodulation. 2021;24:1215 – 1222.
  127. Hayek SM, Veizi E, Hanes M. Intrathecal hydromorphone and bupivacaine combination therapy for post-laminectomy syndrome optimized with patient-activated bolus device. Pain Med. 2016;17:56 1 – 571.
  128. Grider JS, Harned ME, Etscheidt MA. Patient selection and outcomes using a low-dose intrathecal opioid trialing method for chronic nonmalignant pain. Pain Phys. 2011;14:343 – 351.
  129. Grider JS, Etscheidt MA, Harned ME, et al. Trialing and maintenance dosing using a low-dose intrathecal opioid method for chronic nonmalignant pain: a prospective 36-month study. Neuromodulation. 2016;19:206 – 219.
  130. Malheiro L, Gomes A, Barbosa P, Santos L, Sarmento A. Infectious complications of intrathecal drug administration systems for spasticity and chronic pain: 145 patients from a tertiary care center. Neuromodulation. 2015;18:421 – 427.
  131. Farid R. Problem-solving in patients with targeted drug delivery systems. Mo Med. 2017;114:52 – 56.
  132. Sharma K, Marcus JR. Bevacizumab and wound-healing complications: mechanisms of action, clinical evidence, and management recommendations for the plastic surgeon. Ann Plast Surg. 2013;71:434 – 440.
  133. Paice JA, Penn RD, Shott S. Intraspinal morphine for chronic pain: a retrospective, multicenter study. J Pain Symptom Manage. 1996;11:71 – 80.
  134. Hayek SM, Veizi IE, Narouze SN, Mekhail N. Age-dependent intrathecal opioid escalation in chronic noncancer pain patients. Pain Med. 2011;12:1179 – 1189.
  135. Mekhail N, Mahboobi R, Farajzadeh Deroee A, et al. Factors that might impact intrathecal drug delivery (IDD) dose escalation: a longitudinal study. Pain Pract. 2014;14:301 – 308.
  136. Veizi IE, Hayek SM, Narouze S, Pope JE, Mekhail N. Combination of intrathecal opioids with bupivacaine attenuates opioid dose escalation in chronic noncancer pain patients. Pain Med. 2011;12:1481 – 1489.
  137. De Conno F, Caraceni A, Martini C, Spoldi E, Salvetti M, Ventafridda V. Hyperalgesia and myoclonus with intrathecal infusion of high-dose morphine. Pain. 1991;47:337 – 339.
  138. Singla A, Stojanovic MP, Chen L, Mao J. A differential diagnosis of hyperalgesia, toxicity, and withdrawal from intrathecal morphine infusion. Anesth Analg. 2007;105:1816 – 1819.
  139. Aldrete JA, Couto da Silva JM. Leg edema from intrathecal opiate infusions. Eur J Pain. 2000;4:361 – 365.
  140. Veizi E, Tornero-Bold M, Hayek SM. Resolution of intrathecal hydromorphone or morphine-induced peripheral edema by opioid rotation to fentanyl: a case series. Pain Pract. 2016;16:E94 – E98.
  141. Duarte RV, Raphael JH, Southall JL, Baker C, Ashford RL. Intrathecal granuloma formation as a result of opioid delivery: systematic literature review of case reports and analysis against a control group. Clin Neurol Neurosurg. 2012;114:577– 584.
  142. Kumar K, Kelly M, Pirlot T. Continuous intrathecal morphine treatment for chronic pain of nonmalignant etiology: long-term benefits and effi Surg Neurol. 2001;55:79–86 [discussion 86].
  143. Wang Y, Mitchell J, Moriyama K, et al. Age-dependent morphine tolerance development in the rat. Anesth Analg. 2005;100:1733 – 1739.
  144. Hassenbusch SJ, Portenoy RK. Current practices in intraspinal therapy–a survey of clinical trends and decision making. J Pain Symptom Manage. 2000;20:S4 – S11.
  145. Staats P, Whitworth M, Barakat M, Anderson W, Lilienfeld S. The use of implanted programmable infusion pumps in the management of nonmalignant, chronic low-back pain. Neuromodulation. 2007;10:376 – 380.
  146. Mironer YE, Haasis JC, Chapple I, Brown C, Satterthwaite JR. Efficacy and safety of intrathecal opioid/bupivacaine mixture in chronic nonmalignant pain: a double blind, randomized, crossover, multicenter study by the National Forum of Independent Pain Clinicians (NFIPC). Neuromodulation. 2002;5:208 – 213.
  147. Deer TR, Caraway DL, Kim CK, Dempsey CD, Stewart CD, McNeil KF. Clinical experience with intrathecal bupivacaine in combination with opioid for the treatment of chronic pain related to failed back surgery syndrome and metastatic cancer pain of the spine. Spine J. 2002;2:274 – 278.
  148. Veizi IE, Hayek SM, Hanes M, Galica R, Katta S, Yaksh T. Primary hydromorphone-related intrathecal catheter tip granulomas: is there a role for dose and concentration? Neuromodulation. 2016;19:760 – 769.
  149. Delhaas EM, Harhangi BS, Frankema SPG, Huygen FJPM, van der Lugt A. Catheter access port (computed tomography) myelography in intrathecal drug delivery troubleshooting: A case series of 70 procedures. Neuromodulation. 2020;23:949.

  150. Natusch D. Equianalgesic doses of opioids – their use in clinical practice. Br J Pain. 2012;6:43 – 46.
  151. Beaver WT, Wallenstein SL, Houde RW, Rogers A. A comparison of the analgesic effects of pentazocine and morphine in patients with cancer. Clin Pharmacol Ther. 1966;7:740 – 751.
  152. McNicol E, Horowicz-Mehler N, Fisk RA, et al. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. J Pain. 2003;4:231 – 256.
  153. Anderson VC, Cooke B, Burchiel KJ. Intrathecal hydromorphone for chronic nonmalignant pain: a retrospective study. Pain Med. 2001;2:287 – 297.
  154. Calculating total daily dose of opioids for safer dosage. Center for Disease Control and Prevention, National Center for Injury Prevention and Control.

  155. Quigley C. Opioid switching to improve pain relief and drug tolerability. Cochrane Database Syst Rev. 2004;2004:CD004847.
  156. Gammaitoni AR, Fine P, Alvarez N, McPherson ML, Bergmark S. Clinical application of opioid equianalgesic data. Clin J Pain. 2003;19:286 – 297.
  157. Brant JM. Opioid equianalgesic conversion: the right dose. Clin J Oncol Nurs. 2001;5:163 – 165.
  158. Knotkova H, Fine PG, Portenoy RK. Opioid rotation: the science and the limitations of the equianalgesic dose table. J Pain Symptom Manage. 2009;38:426 – 439.
  159. Waara-Wolleat KL, Hildebrand KR, Stewart GR. A review of intrathecal fentanyl and sufentanil for the treatment of chronic pain. Pain Med. 2006;7:251 – 259.
  160. Mercadante S. Opioid rotation for cancer pain: rationale and clinical aspects. Cancer. 1999;86:1856 – 1866.
  161. Indelicato RA, Portenoy RK. Opioid rotation in the management of refractory cancer pain. J Clin Oncol. 2003;21:87s – 91s.
  162. Fine PG, Portenoy RK. Establishing “best practices” for opioid rotation: conclusions of an expert panel. J Pain Symptom Manage. 2009;38:418 – 425.
  163. Sharan AD, Riley J, Falowski S, et al. Association of opioid usage with spinal cord stimulation outcomes. Pain Med. 2018;19:699 – 707.
  164. Hatheway JA, Bansal M, Nichols-Ricker CI. Systemic opioid reduction and discontinuation following implantation of intrathecal drug-delivery systems for chronic pain: a retrospective cohort analysis. Neuromodulation. 2020;23:961 – 969.
  165. Fraifeld EM, Hatheway JA, Ricker CN. Systemic opioid prescribing patterns and total cost of care in patients initiating spinal cord stimulation therapy: a retrospective analysis. Pain Med. 2021;22:784 – 799.
  166. FDA Approved Drug Products. Silver Spring, MD: U.S. Food and Drug Administration; 2006. Accessed August 17, 2020.
  167. Wermeling D, Drass M, Ellis D, et al. Pharmacokinetics and pharmacodynamics of intrathecal ziconotide in chronic pain patients. J Clin Pharmacol. 2003;43:624 – 636.
  168. Yaksh TL, de Kater A, Dean R, Best BM, Miljanich GP. Pharmacokinetic analysis of ziconotide (SNX-111), an intrathecal N-type calcium channel blocking analgesic, delivered by bolus and infusion in the dog. Neuromodulation. 2012;15(6):508.
  169. Sirianni RW, Zheng MQ, Saltzman WM, Huang Y, Carson RE. Direct, quantitative, and noninvasive imaging of the transport of active agents through intact brain with positron emission tomography. Mol Imaging Biol. 2013;15:596 – 605.
  170. Maeyaert J, Buchser E, Van Buyten JP, Rainov NG, Becker R. Patient-controlled analgesia in intrathecal therapy for chronic pain: safety and effective operation of the model 8831 Personal Therapy Manager with a pre-implanted SynchroMed Infusion System. Neuromodulation. 2003;6:133 – 141.
  171. Saulino M, Kim PS, Shaw E. Practical considerations and patient selection for intrathecal drug delivery in the management of chronic pain. J Pain Res. 2014;7:627 – 638.
  172. Deer T, Hagedorn JM. How has ziconotide impacted non-cancer pain management? Expert Opin Pharmacother. 2020;21:507 – 511.
  173. Wang YX, Gao D, Pettus M, Phillips C, Bowersox SS. Interactions of intrathecally administered ziconotide, a selective blocker of neuronal N-type voltage-sensitive calcium channels, with morphine on nociception in rats. Pain. 2000;84:271 – 281.
  174. Alicino I, Giglio M, Manca F, Bruno F, Puntillo F. Intrathecal combination of ziconotide and morphine for refractory cancer pain: a rapidly acting and effective Pain. 2012;153:245 – 249.
  175. Highlights of prescribing information for prialt TerSera Therapeutics.

  176. Smith HS, Deer TR. Safety and efficacy of intrathecal ziconotide in the management of severe chronic pain. Ther Clin Risk Manag. 2009;5:521 – 534.
  177. Brogan SE, Winter NB, Okifuji A. Prospective observational study of patient-controlled intrathecal analgesia: impact on cancer-associated symptoms, breakthrough pain control, and patient satisfaction. Reg Anesth Pain Med. 2015;40:369 – 375.
  178. Brogan SE, Winter NB. Patient-controlled intrathecal analgesia for the management of breakthrough cancer pain: a retrospective review and commentary. Pain Med. 2011;12:1758 – 1768.
  179. Rigoli G, Terrini G, Cordioli Z. Intrathecal Baclofen withdrawal syndrome caused by low residual volume in the pump reservoir: a report of 2 cases. Arch Phys Med Rehabil. 2004;85:2064 – 2066.
  180. Elovic E, Kirshblum SC. Managing spasticity in spinal cord injury: safe administration of bridge boluses during intrathecal Baclofen pump refi J Spinal Cord Med. 2003;26:2 – 4.
  181. Ward M, Mammis A, Barry MT, Heary RF. Novel association between intrathecal drug administration and arachnoiditis ossifi World Neurosurg. 2018;115:400 – 406.
  182. Coyne PJ, Hansen LA, Laird J, Buster P, Smith TJ. Massive hydromorphone dose delivered subcutaneously instead of intrathecally: guidelines for prevention and management of opioid, local anesthetic, and clonidine overdose. J Pain Symptom Manage. 2004;28:273 – 276.

  183. Hurdle MF, Locketz AJ, Smith J. A technique for ultrasound-guided intrathecal drug-delivery system refi Am J Phys Med Rehabil. 2007;86:250 – 251.
  184. Abd-Elsayed A. Pocket fill during intrathecal pump refill: is it a frequent occurrence? Neuromodulation. 2019;22:761.
  185. Maino P, Perez RSGM, Koetsier E. Intrathecal pump refills, pocket fills, and symptoms of drug overdose: a prospective, observational study comparing the injected drug volume vs. the drug volume effectively measured inside the pump. Neuromodulation. 2017;20:733 – 739.
  186. Matthys C, Jacobs M, Rossat J, Perruchoud C. Accuracy of template versus ultrasound identification of the reservoir access port of intrathecal drug delivery Neuromodulation. 2020;23:944 – 948.
  187. Singa RM, Buvanendran A, McCarthy RJ. A comparison of refill procedures and patient outcomes following ultrasound-guided and template-guided intrathecal drug delivery systems with recessed ports. Neuromodulation. 2020;23:938 – 943.
  188. Miracle AC, Fox MA, Ayyangar RN, Vyas A, Mukherji SK, Quint DJ. Imaging evaluation of intrathecal Baclofen pump-catheter systems. AJNR Am J Neuroradiol. 2011;32:1158 – 1164.

  189. Delhaas E, Harhangi B, Frankema S, Huygen F, van der Lugt A. Catheter access port (computed tomography) myelography in intrathecal drug delivery troubleshooting: a case series of 70 procedures. Neuromodulation. 2020;23:949 – 960.
  190. Lew SM, Psaty EL, Abbott R. An unusual cause of overdose after Baclofen pump implantation: case report. Neurosurgery. 2005;56:E624 [discussion: E624].
  191. Ellis JA, Leung R, Winfree CJ. Spinal infusion pump-catheter leak detected by high-resolution 3D computed tomography. J Neurosurg Spine. 2011;15:555 – 557.
  192. Dupoiron D, Carvajal G. High-resolution three-dimensional computed tomography reconstruction as first-line imaging modality to detect intrathecal catheter Neuromodulation. 2018;21:717 – 720.
  193. Hagedorn JM, Bendel MA, Moeschler SM, Lamer TJ, Pope JE, Deer TR. Intrathecal gadolinium use for the chronic pain physician. Neuromodulation. 2019;22:769 – 774.
  194. Nagel SJ, Reddy CG, Frizon LA, et al. Intrathecal therapeutics: device design, access methods, and complication mitigation. Neuromodulation. 2018;21:625.

  195. Galica R, Hayek SM, Veizi IE, Lawrence MM, Khalil AA, McEwan MT. Sudden intrathecal drug delivery device motor stalls: a case series. Reg Anesth Pain Med. 2016;41:135 – 139.
  196. Goel V, Yang Y, Kanwar S, et al. Adverse events and complications associated with intrathecal drug delivery systems: insights from the Manufacturer and User Facility Device Experience (MAUDE) database. Neuromodulation. 2021;24:1181.

  197. Kosturakis A, Gebhardt R. SynchroMed II intrathecal pump memory errors due to repeated magnetic resonance imaging. Pain Phys. 2012;15:475 – 4 77.
  198. Wesemann K, Coffey RJ, Wallace MS, Tan Y, Broste S, Buvanendran A. Clinical accuracy and safety using the Synchromed II intrathecal drug infusion pump. Reg Anesth Pain Med. 2014;39:341 – 346.
  199. Farid R, Binz K, Emerson JA, Murdock F. Accuracy and precision of the SynchroMed II Pump. Neuromodulation. 2019;22:805 – 810.
  200. Rauck R, Deer T, Rosen S, et al. Long-term follow-up of a novel implantable programmable infusion pump. Neuromodulation. 2013;16:163 – 167.
  201. Skalsky AJ, Dalal P, Le J, Ewing E, Yaszay B. Screening intrathecal Baclofen pump systems for catheter patency via catheter access port aspiration. Neuromodulation. 2020;23:1003 – 1008.
  202. Dvorak EM, McGuire JR, Nelson ME. Incidence and identification of intrathecal Baclofen catheter malfunction. PM R. 2010;2:751 – 756.
  203. Delhaas EM, van der Lugt A. Low-dose computed tomography with two- and three-dimensional postprocessing as an alternative to plain radiography for intrathecal catheter visualization: a phantom pilot study. Neuromodulation. 2019;22:818 – 822.
  204. Motta F, Antonello CE. Analysis of complications in 430 consecutive pediatric patients treated with intrathecal Baclofen therapy: 14-year experience. J Neurosurg Pediatr. 2014;13:301 – 306.
  205. Shao J, Frizon L, Machado A, et al. Occlusion of the Ascenda catheter in a patient with pump twiddlers’s syndrome: a case report. Anesth Pain Med. 2018;8(2), e65312.

  206. Saulino M, Anderson DJ, Doble J, et al. Best practices for intrathecal Baclofen therapy: troubleshooting. Neuromodulation. 2016;19:632–641.
  207. Frémondière F, Lacoeuille F, Sher A, et al. Assessment of intrathecal Baclofen pump malfunction: a new algorithm including nuclear medicine investigation. Ann Phys Rehabil Med. 2016;59:e140 – e141.
  208. Morgalla M, Fortunato M, Azam A, Tatagiba M, Lepski G. High-resolution three-dimensional computed tomography for assessing complications related to intrathecal drug delivery. Pain Phys. 2016;19:E775 – E780.
  209. Saulino M, Turner M, Miesel K, et al. Can cerebrospinal fluid pressure detect catheter complications in patients who experience loss of effectiveness with intrathecal Baclofen therapy? Neuromodulation. 2017;20:187 – 197.
  210. Delhaas EM, van Assema DME, Fröberg AC, et al. Isotopic scintigraphy in intrathecal drug delivery failure: a single-institution case series. Neuromodulation. 2021;24:1190 – 1198.

  211. Yowtak J, Cato K, Williams H, et al. Indium 111 diethylenetriamine pentaacetic acid scintigraphy in the identification and management of intrathecal pump PM & R. 2013;5:32 – 38.
  212. Maus TP, Schueler BA, Magnuson DJ, Magnuson D. Relative conspicuity of gadolinium-based contrast agents in interventional pain procedures. Pain Med. 2017;18:651 – 654.
  213. Safriel Y, Ali M, Hayt M, Ang R. Gadolinium use in spine procedures for patients with allergy to iodinated contrast-experience of 127 procedures. AJNR Am J Neuroradiol. 2006;27:1194 – 1197.
  214. Akbar JJ, Luetmer PH, Schwartz KM, Hunt CH, Diehn FE, Eckel LJ. The role of MR myelography with intrathecal gadolinium in localization of spinal CSF leaks in patients with spontaneous intracranial hypotension. AJNR Am J Neuroradiol. 2012;33:535 – 540.
  215. Provenzano DA, Pellis Z, DeRiggi L. Fatal gadolinium-induced encephalopathy following accidental intrathecal administration: a case report and a comprehensive evidence-based review. Reg Anesth Pain Med. 2019;44:721 – 729.
  216. Maus T. Intrathecal gadolinium: a fatal flaw. Reg Anesth Pain Med. 2019;44:687 – 688.
  217. Staats PS. Complications of intrathecal therapy. Pain Med. 2008;9:S102 – S107.
  218. Johnson ML, Visser EJ, Goucke CR. Massive clonidine overdose during refill of an implanted drug delivery device for intrathecal analgesia: a review of inadvertent soft-tissue injection during implantable drug delivery device refills and its man Pain Med. 2011;12:1032 – 1040.
  219. Perruchoud C, Bovy M, Rutschmann B, Durrer A, Buchser E. Silicone septum leakage at the origin of a drug overdose in a patient implanted with an intrathecal pump. Neuromodulation. 2013;16:467, 63 [discussion: 469].
  220. Gofeld M, McQueen CK. Ultrasound-guided intrathecal pump access and prevention of the pocket. Pain Med. 2011;12:607 – 611.
  221. Saulino M, Gofeld M. “Sonology” of programmable intrathecal pumps. Neuromodulation. 2014;17:696 – 698 [discussion: 698].
  222. Maneyapanda MB, Chang Chien GC, Mattie R, Amorapanth P, Reger C, McCormick ZL. Ultrasound guidance for technically challenging intrathecal Baclofen pump refill: Three Cases and Procedure Description. Am J Phys Med Rehabil. 2016;95:692 – 697.
  223. Maino P, Koetsier E, Perez RS. The accuracy of template-guided refill technique of intrathecal pumps controlled by fluoroscopy: an observational study. Neuromodulation. 2015;18:428 – 432.
  224. Maino P, van Kuijk SMJ, Perez RSGM, Koetsier E. Ease of fill port access during the ultrasound-guided vs. the blind refill technique of intrathecal drug delivery systems with a raised septum, a prospective comparison study. Neuromodulation. 2018;21:641 – 647.
  225. Maino P, van Kuijk SMJ, Perez RSGM, Koetsier E. Refill procedures of intrathecal drug delivery systems with a recessed fill port on the pump surface: a prospective comparison study of ultrasound-guided vs. blind refill technique. Neuromodulation. 2019;22:799 – 804.
  226. Johns MW. Reliability and factor analysis of the Epworth Sleepiness Scale. Sleep. 1992;15:376 – 381.
  227. Nagappa M, Liao P, Wong J, et al. Validation of the STOP-Bang Questionnaire as a screening tool for obstructive sleep apnea among different populations: a systematic review and meta-analysis. PLOS ONE. 2015;10, e0143697.
  228. Dronge AS, Perkal MF, Kancir S, Concato J, Aslan M, Rosenthal RA. Long-term glycemic control and postoperative infectious complications. Arch Surg. 2006;141:375 – 380 [discussion: 380].
  229. Zerr KJ, Furnary AP, Grunkemeier GL, Bookin S, Kanhere V, Starr A. Glucose control lowers the risk of wound infection in diabetics after open heart operations. Ann Thorac Surg. 1997;63:356–361.
  230. Buist AS, Sexton GJ, Nagy JM, Ross BB. The effect of smoking cessation and modification on lung function. Am Rev Respir Dis. 1976;114:115 – 122.
  231. Kinsella JB, Rassekh CH, Wassmuth ZD, Hokanson JA, Calhoun KH. Smoking increases facial skin flap complications. Ann Otol Rhinol Laryngol. 1999;108:139 – 142.
  232. Schipmann S, Akalin E, Doods J, Ewelt C, Stummer W, Suero Molina E. When the infection hits the wound: matched case-control study in a neurosurgical patient collective including systematic literature review and risk factors analysis. World Neurosurg. 2016;95:178 – 189.
  233. Wyles CC, Hevesi M, Osmon DR, et al. John Charnley Award: increased risk of prosthetic joint infection following primary total knee and hip arthroplasty with the use of alternative antibiotics to cefazolin. Bone Joint J. 2019;101:9 – 15.
  234. Blumenthal KG, Ryan EE, Li Y, Lee H, Kuhlen JL, Shenoy ES. The impact of a reported penicillin allergy on surgical site
    infection risk. Clin Infect Dis.     2018;66:329 – 336.

  235. Henderson JM, Levy RM, Bedder MD, et al. NANS training requirements for spinal cord stimulation devices: selection, implantation, and follow-up. Neuromodulation. 2009;12:171 – 174.
  236. Bratzler DW, Houck PM, et al, Surgical Infection Prevention Guidelines Writers Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. Clin Infect Dis. 2004;38:1706 – 1715.
  237. Alexander JW, Solomkin JS, Edwards MJ. Updated recommendations for control of surgical site infections. Ann Surg. 2011;253:1082 – 1093.
  238. Bratzler DW, Dellinger EP, Olsen KM, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Surg Infect (Larchmt). 2013;14:73 – 156.
  239. Nadherny W, Anderson B, Abd-Elsayed A. Perioperative and periprocedural care of patients with intrathecal pump therapy. Neuromodulation. October;22:775.

  240. Magill ST, Wang P, Eller JL, Burchiel KJ. Differentiating intrathecal catheter tip granulomas from normal magnetic resonance image distortion caused by metallic catheter tips. Neurosurgery. 2008;62(1):242 – 248.
  241. Schultz DM, Abd-Elsayed A, Calodney A, Stromberg K, Weaver T, Spencer RJ. Targeted drug delivery for chronic nonmalignant pain: longitudinal data from the Product Surveillance Registry. Neuromodulation. 2021;24:1167 – 1175.
  242. Narouze S, Benzon HT, Provenzano DA, et al. Interventional spine and pain procedures in patients on antiplatelet and anticoagulant medications: guidelines from the American Society of Regional Anesthesia and Pain Medicine, the European Society of Regional Anaesthesia and Pain Therapy, the American Academy of Pain Medicine, the International Neuromodulation Society, the North American Neuromodulation Society, and the World Institute of Pain. Reg Anesth Pain Med. 2015;40:182 – 212.
  243. Petraglia FW, Farber SH, Gramer R, et al. The incidence of spinal cord injury in implantation of percutaneous and paddle electrodes for spinal cord stimulation. Neuromodulation. 2016;19:85 – 90.
  244. Mendoza PA, Narula S, McIntyre WF, et al. Continued versus interrupted direct oral anticoagulation for cardiac electronic device implantation: a systematic Pacing Clin Electrophysiol. 2020;43:1373 – 1381.
  245. Birnie D, Healey JS, Krahn A, et al. Bridge or continue coumadin for device surgery: a randomized controlled trial rationale and design. Curr Opin Cardiol. 2009;24:82 – 87.

  246. Delhaas EM, Beersen N, Redekop WK, Klazinga NS. Long-term outcomes of continuous intrathecal Baclofen infusion for treatment of spasticity: a prospective multicenter follow-up study. Neuromodulation. 2008;11:227 – 236.
  247. Stetkarova I, Yablon SA, Kofler M, Stokic DS. Procedure – and device-related complications of intrathecal Baclofen administration for management of adult muscle hypertonia: a review. Neurorehabil Neural Repair. 2010;24:609–619.
  248. Awaad Y, Rizk T, Siddiqui I, Roosen N, McIntosh K, Waines GM. Complications of intrathecal Baclofen pump: prevention and cure. ISRN Neurol. 2012;2012, 575168.
  249. Delhaas EM, Huygen FJPM. Complications associated with intrathecal drug delivery systems. BJA Educ. 2020;20:51 – 57.

  250. Kamran S, Wright BD. Complications of intrathecal drug delivery systems. Neuromodulation. 2001;4:111 – 115.

  251. Stearns LM, Abd-Elsayed A, Perruchoud C, et al. Intrathecal drug delivery systems for cancer pain: an analysis of a prospective, multicenter product surveillance registry. Anesth Analg. 2020;130:289 – 297.

  252. Motta F, Antonello CE. Comparison between an Ascenda and a silicone catheter in intrathecal Baclofen therapy in pediatric patients: analysis of complications. J Neurosurg Pediatr. 2016;18:493 – 498.
  253. Bayliss CE, Beanlands DS, Baird RJ. The pacemaker-twiddler’s syndrome: a new complication of implantable transvenous pacemakers. Can Med Assoc J. 1968;99:371 – 373.
  254. Moens M, De Smedt A, Brouns R. Opioid withdrawal due to Twiddler syndrome.
  255. Yaksh TL, Eddinger KA, Kokubu S, et al. Mast cell degranulation and fibroblast activation in the morphine-induced spinal mass: role of mas-related G protein-coupled receptor signaling. Anesthesiology. 2019;131:132–147.

  256. Frizon LA, Sabharwal NC, Maiti T, et al. Removal of intrathecal catheters used in drug delivery systems. Neuromodulation. 2018;21:665 – 668.

  257. Stearns LJ, Narang S, Albright Jr RE, et al. Assessment of health care utilization and cost of targeted drug delivery and conventional medical management vs conventional medical management alone for patients with cancer-related pain. JAMA Netw Open. 2019;2, e191549.
  258. Stearns LJ, Hinnenthal JA, Hammond K, Berryman E, Janjan NA. Health services utilization and payments in patients with cancer pain: a comparison of intrathecal drug delivery vs. conventional medical management. Neuromodulation. 2016;19:196 – 205.
  259. Brogan SE, Winter NB, Abiodun A, Safarpour R. A cost utilization analysis of intrathecal therapy for refractory cancer pain: identifying factors associated with cost benefi Pain Med. 2013;14:478 – 486.
  260. Health Quality Ontario. Intrathecal drug delivery systems for cancer pain: a health technology assessment. Ont Health Technol Assess Ser. 2016;16:1 – 51.
  261. Kumar K, Hunter G, Demeria DD. Treatment of chronic pain by using intrathecal drug therapy compared with conventional pain therapies: a cost-effectiveness J Neurosurg. 2002;97:803 – 810.
  262. Kumar K, Rizvi S, Bishop S. Cost effectiveness of intrathecal drug therapy in management of chronic nonmalignant pain. Clin J Pain. 2013;29:138 – 145.
  263. Biggs SA, Duarte RV, Raphael JH, Ashford RL. Influence of a latent period in QALY analysis: pilot study of intrathecal drug delivery systems for chronic non-malignant pain. Br J Neurosurg. 2011;25:401 – 406.
  264. Dewilde S, Verdian L, Maclaine GD. Cost-effectiveness of ziconotide in intrathecal pain management for severe chronic pain patients in the UK. Curr Med Res Opin. 2009;25:2007 – 2019.
  265. de Lissovoy G, Matza LS, Green H, Werner M, Edgar T. Cost-effectiveness of intrathecal Baclofen therapy for the treatment of severe spasticity associated with cerebral palsy. J Child Neurol. 2007;22:49 – 59.
  266. Hoving MA, Evers SM, Ament AJ, van Raak EP, Vles JS. Intrathecal Baclofen therapy in children with intractable spastic cerebral palsy: a cost-effectiveness Dev Med Child Neurol. 2008;50:450 – 455.
  267. Saulino M, Guillemette S, Leier J, Hinnenthal J. Medical cost impact of intrathecal Baclofen therapy for severe spasticity. Neuromodulation. 2015;18:141–149 [discussion: 149].
  268. Duarte RV, Lambe T, Raphael JH, Eldabe S, Andronis L. Intrathecal drug delivery systems for the management of chronic noncancer pain: a systematic review of economic evaluations. Pain Pract. 2018;18:666–686.
  269. Fang H, Frean M, Sylwestrzak G, Ukert B. Trends in disenrollment and reenrollment within US commercial health insurance plans, 2006–2018. JAMA Netw Open. 2022;5, e220320.
  270. Ramsey SD, Willke RJ, Glick H, et al. Cost-effectiveness analysis alongside clinical trials II-An ISPOR Good Research Practices Task Force report. Value Health. 2015;18:161–172.
  271. Petrou S, Gray A. Economic evaluation alongside randomized controlled trials: design, conduct, analysis, and reporting. BMJ. 2011;342, d1548.
  272. Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. 4th ed. Oxford University Press; 2015.
  273. Glick HA, Doshi JA, Sonnad SS, Polsky D. Economic Evaluation in Clinical Trials. 2nd Oxford University Press; 2015.
  1. Onofrio BM, Yaksh TL, Arnold PG. Continuous low-dose intrathecal morphine administration in the treatment of chronic pain of malignant origin. Mayo Clin Proc. 1981;56:516–520.
  2. Follett KA, Hitchon PW, Piper J, Kumar V, Clamon G, Jones MP. Response of intractable pain to continuous intrathecal morphine: a retrospective study. Pain. 1992;49:21–25.
  3. Winkelmüller M, Winkelmüller W. Long-term effects of continuous intrathecal opioid treatment in chronic pain of nonmalignant etiology. J Neurosurg. 1996;85:458–467.
  4. Bennett G, Burchiel K, Buchser E, et al. Clinical guidelines for intraspinal infusion: report of an expert panel. PolyAnalgesic Consensus Conference 2000. J Pain Symptom Manage. 2000;20:S37–S43.
  5. Deer T, Krames ES, Hassenbusch SJ, et al. Polyanalgesic consensus conference 2007: recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation. 2007;10:300–328.
  6. Deer TR, Prager J, Levy R, et al. Polyanalgesic Consensus Conference 2012: recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation. 2012;15:436–464 [discussion: 464–436].
  7. Deer TR, Prager J, Levy R, et al. Polyanalgesic Consensus Conference–2012: recommendations on trialing for intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation. 2012;15:420–435 [discussion: 435].
  8. Deer TR, Prager J, Levy R, et al. Polyanalgesic Consensus Conference–2012: consensus on diagnosis, detection, and treatment of catheter-tip granulomas (inflammatory masses). Neuromodulation. 2012;15:483–495 [discussion 496].
  9. Deer TR, Levy R, Prager J, et al. Polyanalgesic Consensus Conference–2012: recommendations to reduce morbidity and mortality in intrathecal drug delivery in the treatment of chronic pain. Neuromodulation. 2012;15:467–482 [discussion 482].
  10. Deer TR, Pope JE, Hayek SM, et al. The Polyanalgesic Consensus Conference (PACC®) recommendations on intrathecal drug infusion systems best practices and guidelines.
    Neuromodulation. 2017;20:96 – 132.

  11. Deer TR, Hayek SM, Pope JE, et al. The Polyanalgesic Consensus Conference (PACC®) recommendations for trialing of intrathecal drug delivery infusion therapy. Neuromodulation. 2017;20:133–154.
  12. Deer TR, Pope JE, Hayek SM, et al. The Polyanalgesic Consensus Conference (PACC®) recommendations for intrathecal drug delivery for improving safety and mitigating risk.
    Neuromodulation. 2017;20:155–176.

  13. Silverman E. Everything you need to know about the Sunshine Act. BMJ. 2013;347, f4704.
  14. Harris RP, Helfand M, Woolf SH, et al. Third U.S. Preventive Services Task Force. a review of the process. Am J Prev
    Med    . 2001;20:21–35    .

  15. Doleys DM. Pain: Dynamics and Complexities. Oxford University Press; 2014.
  16. Block AR, Darwer DB. Presurgical Psychological Screening: Understanding Patients. Improving Outcomes. American Psychological Association Books; 2013.
  17. Bendinger T, Plunkett N, Poole D, Turnbull D. Psychological factors as outcome predictors for spinal cord stimulation.
    Neuromodulation. 2015;18:465–471 [dis    cussion 471].

  18. Sparkes E, Duarte RV, Mann S, Lawrence TR, Raphael JH. Analysis of psychological characteristics impacting spinal cord stimulation treatment outcomes: a prospective assessment. Pain Phys. 2015;18:E369–E377.
  19. Robb LP, Cooney JM, McCrory CR. Evaluation of spinal cord stimulation on the symptoms of anxiety and depression and pain
    intensity in patients with failed     back surgery syndrome. Ir J Med Sci. 2017;186:767–771.

  20. Fama CA, Chen N, Prusik J, et al. The use of preoperative psychological evaluations to predict spinal cord stimulation success: our experience and a review of the literature. Neuromodulation. 2016;19:429–436.
  21. Maatta J, Martikainen A, Pakarinen M, et al. High level of childhood trauma predicts a poor response to spinal cord stimulation in chronic neuropathic pain. Pain Phys. 2019;22:E37–E44.
  22. Sheldon BL, Khazen O, Feustel PJ, et al. Correlations between family history of psychiatric illnesses and outcomes of spinal cord stimulation. Neuromodulation. 2020;23:667–672.
  23. Prabhala T, Kumar V, Gruenthal E, et al. Use of a psychological evaluation tool as a predictor of spinal cord stimulation outcomes. Neuromodulation. 2019;22:194– 199.
  24. Grinberg AM, D’Eon MS, Ellison JK, Rutledge T, Castellanos J, Chakravarthy KV. A revised psychosocial assessment model for implantable pain devices to improve their evidence basis and consensus with updated pain management Pain Management 2019;9:139–149.
  25. Thomson S, Huygen F, Prangnell S, et al. Appropriate referral and selection of patients with chronic pain for spinal cord stimulation: European consensus recommendations and e-health tool. Eur J Pain. 2020;24:1169–1181.
  26. Kim P, Deer T. Managing intrathecal drug delivery devices in a global pandemic. Neuromodulation. 2020;23:716–717.
  27. Perez J, Niburski K, Stoopler M, Ingelmo P. Telehealth and chronic pain management from rapid adaptation to long-term implementation in pain medicine: a narrative review. PAIN Rep. 2021;6:e912.
  28. Chou R, Turner JA, Devine EB, et al. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med. 2015;162:276–286.
  29. Gery P, Guy Jr , Zhang Kun, Bohm Michele K, et al. Vital Signs: changes in opioid prescribing in the United States, 2006–2015. Morbidity and Mortality Weekly Report. 2017;66:697–704.
  30. Vital Signs: Overdoses of prescription opioid pain relievers—United States, 1999 – MMWR. Morbidity and Mortality Wkly Report. 2011;60:1487–1492.
  31. Eccleston C, Fisher E, Thomas KH, et al. Interventions for the reduction of prescribed opioid use in chronic non-cancer pain. Cochrane Database Syst Rev. 2017;11, CD010323.
  32. Fishbain DA, Pulikal A. Does opioid tapering in chronic pain patients result in improved pain or same pain vs increased pain at taper completion? a structured evidence-based systematic review. Pain Med. 2019;20:2179–2197.
  33. Frank JW, Lovejoy TI, Becker WC, et al. Patient outcomes in dose reduction or discontinuation of long-term opioid therapy: a systematic review. Ann Intern Med. 2017;167:181–191.
  34. Sandhu H, Underwood M, Furlan AD, Noyes J, Eldabe S. What interventions are effective to taper opioids in patients with chronic pain? BMJ. 2018;362:k2990.
  35. Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC clinical practice guideline for prescribing opioids for pain — United States, 2022. MMWR Recomm Rep. 2022;71:1–95.
  36. Sandhu HK, Abraham C, Alleyne S, et al. Testing a support programme for opioid reduction for people with chronic non-malignant pain: the I-WOTCH randomized controlled trial protocol. BMJ Open. 2019;9, e028937.
  37. Darnall BD, Mackey SC, Lorig K, et al. Comparative effectiveness of cognitive behavioral therapy for chronic pain and chronic pain self-management within the context of voluntary patient-centered prescription opioid tapering: the EMPOWER Study Protocol. Pain Med. 2020;21:1523–1531.
  38. Darnall BD, Roy A, Chen AL, et al. Comparison of a single-session pain management skills intervention with a single-session health education intervention and 8 sessions of cognitive behavioral therapy in adults with chronic low back pain: a randomized clinical trial. JAMA Netw Open. 2021;4, e2113401.
  39. Hill R, Duarte R, Eldabe S, et al. Safe and effective gradual reduction (tapering) of opioids in people with chronic non-cancer pain: systematic review of effects, barriers and facilitators and inequalities to inform service design in the NHS.
  40. Abd-Elsayed A, Karri J, Michael A, et al. Intrathecal drug delivery for chronic pain syndromes: a review of considerations in practice management. Pain Phys. 2020;23:E591–E617.
  41. Abd-Sayed A, Fiala K, Weisbein J, et al. Intrathecal Drug Delivery Systems Survey: trends in utilization in pain practice. J Pain Res. 2022;15:1305–1314.
  42. Karri J, Singh M, Modi DJ, et al. Combination intrathecal drug therapy strategies for pain management. Pain Phys. 2021;24:549–569.
  43. Guay DR. Adjunctive agents in the management of chronic pain. Pharmacotherapy. 2001;21:1070–1081.
  44. Wallace M, Webster L, Rauck R, et al. Effect of concomitant antidepressant and anticonvulsant use on adverse events in patients receiving intrathecal ziconotide in a long-term extension study. J Pain. 2014;15S74: abstract #393.
  45. Bair MJ, Robinson RL, Katon W, Kroenke K. Depression and pain comorbidity: a literature review. Arch Intern Med. 2003;163:2433–2445.
  46. Rayner L, Hotopf M, Petkova H, Matcham F, Simpson A, McCracken LM. Depression in patients with chronic pain attending specialized pain treatment center: prevalence and impact on health care costs. Pain. 2016;157:1472–1479.
  47. Deer T, Chapple I, Classen A, et al. Intrathecal drug delivery for treatment of chronic low back pain: report from the National Outcomes Registry for Low BackPain Med. 2004;5:6 –13.
  48. Feinberg SD, Gatchel RJ, Stanos S, Feinberg R, Johnson – Montieth V. Interdisciplinary functional restoration and pain programs. In: Deer TR, Leong MS, Ray AL, eds. Treatment of Chronic Pain by Integrative Approaches. Springer; 2014:169 –182.
  49. LaRowe LR, Ditre JW. Pain, nicotine, and tobacco smoking: current state of the Pain. 2020;161:1688 –1693.
  50. De Gregori M, Muscoli C, Schatman ME, et al. Combining pain therapy with lifestyle: the role of personalized nutrition and nutritional supplements according to the SIMPAR Feed Your Destiny approach. J Pain Res. 2016;9:1179 –1189.
  51. Narouze S, Souzdalnitski D. Obesity and chronic pain:
    systematic review of prevalence and implications for pain practice. Reg Anesth Pain Med. 2015;40:91    .

  52. Stokes A, Lundberg DJ, Hempstead K, Berry KM, Baker JF,
    Preston SH. Obesity and incident prescription opioid use in the U.S., 2000–2015. Am J Prev Med. 2020;58:766 – 775.

  53. US FDA. Use Caution with Implanted Pumps for Intrathecal Administration of Medicines for Pain Management: FDA Safety Communication. November 14, 2018:2 – 5.
  54. Deer T, Kim P, Pope JE, et al. Physician guidance on the use of
    off-labeled drugs in intrathecal drug delivery systems for chronic pain. Neuromodulation. 2019;22:765 – 768.

  55. Konrad PE, Huffman JM, Stearns LM, et al. Intrathecal drug delivery systems (IDDS): the implantable systems performance registry (ISPR). Neuromodulation. 2016;19:848 – 856.
  56. Prager J, Deer T, Levy R, et al. Best practices for intrathecal drug delivery for pain. Neuromodulation. 2014;17:354 – 372 [discussion 372].
  57. US Pharmacopeia. Chapter 797. Accessed August 4, 2023.
  58. Copley S, Yassa PE, Batterham AM, et al. A clinical evaluation of the accuracy of an intrathecal drug delivery device. Neuromodulation. 2023;26:1240 – 1246.
  59. Hamza M, Doleys DM, Saleh, Medvedovsky A, Verdolin MH, Hamza MA. Prospective, randomized, single-blinded, head-to-head long-term outcome study comparing intrathecal boluses with continuous infusion trialing techniques prior to implantation of drug delivery systems for the treatment of severe intractable chronic nonmalignant pain. Neuromodulation. 2015;18:636 – 648 [discussion 649].
  60. Bernards CM. Cerebrospinal fluid and spinal cord distribution of Baclofen and bupivacaine during slow intrathecal infusion in pigs. Anesthesiology. 2006;105:169 – 178.
  61. Yaksh TL, Fisher CJ, Hockman TM, Wiese AJ. Current and future issues in the development of spinal agents for the management of pain. Curr Neuropharmacol. 2017;15:232 – 259.
  62. Hsu Y, Hettiarachchi HD, Zhu DC, Linninger AA. The frequency and magnitude of cerebrospinal fluid pulsations influence intrathecal drug distribution: key factors for interpatient variability. Anesth Analg. 2012;115:386–394.
  63. Pharmacology of intrathecally administered agents for treatment of spasticity and pain. In: Hayek SM, Joseph PN, Mekhail NA, eds. Seminars in Pain Medicine. Elsevier; 2003.
  64. Kroin JS, Ali A, York M, Penn RD. The distribution of medication along the spinal canal after chronic intrathecal administration. Neurosurgery. 1993;33:226 – 230 [discussion 30].
  65. Ummenhofer WC, Arends RH, Shen DD, Bernards CM. Comparative spinal distribution and clearance kinetics of intrathecally administered morphine, fentanyl, alfentanil, and sufentanil. Anesthesiology. 2000;92:739 – 753.
  66. Dominguez E, Sahinler B, Bassam D, et al. Predictive value of intrathecal narcotic trials for long-term therapy with implantable drug administration systems in chronic non-cancer pain patients. Pain Pract. 2002;2:315 – 325.
  67. Bernards CM. Understanding the physiology and pharmacology of epidural and intrathecal opioids. Best Pract Res Clin Anaesthesiol. 2002;16:489 – 505.
  68. Bernards CM. Recent insights into the pharmacokinetics of spinal opioids and the relevance to opioid selection. Curr Opin Anaesthesiol. 2004;17:441 – 447.
  69. Sandler AN, Stringer D, Panos L, et al. A randomized, double-blind comparison of lumbar epidural and intravenous fentanyl infusions for postthoracotomy pain Analgesic, pharmacokinetic, and respiratory effects. Anesthesiology. 1992;77:626 – 634.
  70. Ade T, Roh J, Sharma G, et al. Comparative effectiveness of
    targeted intrathecal drug delivery using a combination of bupivacaine with either low-dose fentanyl or hydromorphone in chronic back pain patients with lumbar postlaminectomy Pain Med. 2020;21:1921 – 1928.

  71. Galica RJ, Hayek SM, Veizi E, et al. Intrathecal trialing of continuous infusion combination therapy with hydromorphone and bupivacaine in failed back surgery patients. Neuromodulation. 2018;21:648 – 654.
  72. Hayek SM, Jones BA, Veizi E, Tran TQ, DeLozier SJ. Efficacy of continuous intrathecal infusion trialing with a mixture of fentanyl and bupivacaine in chronic low back pain patients. Pain Med. 2023;24:796 – 808.
  73. Burton AW, Deer TR, Wallace MS, Rauck RL, Grigsby E. Considerations and methodology for trialing ziconotide. Pain Phys. 2010;13:23 – 33.
  74. Ver Donck A, Collins R, Rauck RL, Nitescu P. An open-label, multicenter study of the safety and efficacy of intrathecal ziconotide for severe chronic pain when delivered via an external pump. Neuromodulation. 2008;11:103 – 111.
  75. Mohammed SI, Eldabe S, Simpson KH, et al. Bolus intrathecal injection of ziconotide (Prialt(R)) to evaluate the option of continuous administration via an implanted intrathecal drug delivery (ITDD) system: a pilot study. Neuromodulation. 2013;16:576 – 581 [discussion 582].
  76. Bäckryd E, Sörensen J, Gerdle B. Ziconotide trialing by intrathecal bolus injections: an open-label non-randomized clinical trial in postoperative/posttraumatic neuropathic pain patients refractory to conventional treatment. Neuromodulation. 2015;18:404 – 413.
  77. Hayek SM, Hanes MC, Wang C, Veizi IE. Ziconotide combination intrathecal therapy for noncancer pain is limited secondary to delayed adverse effects: a case series with a 24-month follow-up. Neuromodulation. 2015;18:397 – 403.
  78. Pope JE, Deer TR. Intrathecal pharmacology update: novel dosing strategy for intrathecal monotherapy ziconotide on efficacy and sustainability. Neuromodulation. 2015;18:414 – 420.
  79. Deer T, Rauck RL, Kim P, et al. Effectiveness and safety of intrathecal ziconotide: interim analysis of the Patient Registry of Intrathecal Ziconotide Management (PRIZM). Pain Pract. 2018;18:230 – 238.
  80. Henry-Feugeas MC, Idy-Peretti I, Baledent O, et al. Origin of subarachnoid cerebrospinal fluid pulsations: a phase-contrast MR analysis. Magn Reson Imaging. 2000;18:387 – 395.
  81. Daouk J, Bouzerar R, Baledent O. Heart rate and respiration
    influence on macroscopic blood and CSF flows. Acta Radiol. 2017;58:977 – 982.

  82. Brogan SE, Odell DW, Sindt JE, et al. Dorsal versus ventral intrathecal catheter tip location and effect on dose escalation and opioid use in patients with cancer pain. Neuromodulation. 2023;26:1233 – 1239.
  83. Urits I, Petro J, Viswanath O, Aner M. Retrograde placement of an intrathecal catheter for chronic low pelvic cancer pain. J Clin Anesth. 2019;54:43 – 44.
  84. Hayek SM, Sweet JA, Miller JP, Sayegh RR. Successful management of corneal neuropathic pain with intrathecal
    targeted drug delivery. Pain Med. 2016;17:1302 – 1307.

  85. Moman RN, Rogers JM, Pittelkow TP. High cervical intrathecal
    targeted drug delivery: a case report of refractory oropharyngeal cancer pain. Case Rep Oncol Med. 2019;2019, 2098921    .

  86. Enzmann DR, Pelc NJ. Cerebrospinal fluid flow measured by phase-contrast cine AJNR Am J Neuroradiol. 1993;14:1301–1397 [discussion 1309 – 1310].
  87. Dreha-Kulaczewski S, Joseph AA, Merboldt KD, Ludwig HC, Gärtner J, Frahm J. Inspiration is the major regulator of human CSF flow. J Neurosci. 2015;35:2485.

  88. Stockman HW. Effect of anatomical fine structure on the dispersion of solutes in the spinal subarachnoid space. J Biomech Eng. 2007;129:666 – 675.

  89. Stoquart-ElSankari S, Balédent O, Gondry-Jouet C, Makki M, Godefroy O, Meyer ME. Aging effects on cerebral blood and cerebrospinal fluid flows. J Cereb Blood Flow Metab. 2007;27:1563 – 1572.

  90. Shin BS, Kim CS, Sim WS, et al. A comparison of the effects of preanesthetic administration of crystalloid versus colloid on intrathecal spread of isobaric spinal anesthetics and cerebrospinal fluid movement. Anesth Analg. 2011;112:924–930.

  91. Flack SH, Anderson CM, Bernards C. Morphine distribution in the spinal cord after chronic infusion in pigs. Anesth Analg. 2011;112:460–464.

  92. Flack SH, Bernards CM. Cerebrospinal fluid and spinal cord distribution of hyperbaric bupivacaine and Baclofen during slow intrathecal infusion in pigs. Anesthesiology. 2010;112:165–173.

  93. Hejtmanek MR, Harvey TD, Bernards CM. Measured density
    and calculated baricity of custom-compounded drugs for chronic intrathecal infusion. Reg Anesth Pain Med. 2011;36:7 – 11.

  94. van der Plas AA, Marinus J, Eldabe S, Buchser E, van Hilten JJ. The lack of efficacy of different infusion rates of intrathecal Baclofen in complex regional pain syndrome: a randomized, double-blind, crossover study. Pain Med. 2011;12:459.
  95. Perruchoud C, Eldabe S, Durrer A, et al. Effects of flow rate modifications on reported analgesia and quality of life in chronic pain patients treated with continuous intrathecal drug therapy. Pain Med. 2011;12:571 – 576.
  96. Eldabe S, Duarte RV, Madzinga G, et al. Comparison of the effects of intermittent boluses to simple continuous infusion on patients’ global perceived effect in intrathecal therapy for pain: A randomized double-blind crossover study. Pain Med. 2017;18:924 – 931.
  97. Hildebrand KR, Page LM, Billstrom TM, et al. Characterization of effect of repeated bolus or continuous intrathecal infusion of morphine on spinal mass formation in the dog. Neuromodulation. 2019;22:790 – 798.
  98. Robinson S, Robertson FC, Dasenbrock HH, O’Brien CP, Berde
    C, Padua H. Image-guided intrathecal Baclofen pump
    catheter implantation: a technical note and case series. J Neurosurg Spine. 2017;26:621–627.

  99. Thakur SK, Rubin BA, Harter DH. Long-term follow-up for lumbar intrathecal Baclofen catheters placed using the paraspinal subfascial technique. J Neurosurg Pediatr. 2016;17:357–360.
  100. Devine O, Harborne A, Lo WB, Weinberg D, Ciras M, Price R.
    Unusual placement of intrathecal Baclofen pumps: report of two cases. Acta Neurochir (Wien). 2016;158:167 – 170.

  101. Narang S, Srinivasan SK, Zinboonyahgoon N, Sampson CE. Upper antero-medial thigh as an alternative site for implantation of intrathecal pumps: a case series. Neuromodulation. 2016;19:655 – 663.
  102. Deer TR, Provenzano DA, Hanes M, et al. The neurostimulation
    Appropriateness Consensus Committee (NACC®)
    recommendations for infection prevention and Neuromodulation. 2017;20:31 – 50.

  103. Bakhsheshian J, Dahdaleh NS, Lam SK, Savage JW, Smith ZA.
    The use of vancomycin powder in modern spine surgery:
    systematic review and meta-analysis of the clinical evidence. World Neurosurg. 2015;83:816 – 823.

  104. CDC issues recommendations for preventing spread of vancomycin resistance. Am J Health Syst Pharm. 1995;52:1272 – 1274.
  105. Desai VR, Raskin JS, Mohan A, et al. A standardized protocol to reduce pediatric Baclofen pump infections: a quality improvement initiative. J Neurosurg Pediatr. 2018;21:395–400.
  106. Nagel SJ, Frizon L, Maiti T, et al. Contemporary approaches
    to preventing and treating infections of novel intrathecal neurostimulation devices. World Neurosurg. 2019;128:e397 – e408.

  107. Arocho-Quinones EV, Huang CC, Ward BD, Pahapill PA. Care
    bundle approach to minimizing infection rates after neurosurgical implants for neuromodulation: a single-surgeon experience. World Neurosurg. 2019;128:e87 – e97.

  108. Scanlon MM, Gazelka HM, Moeschler SM, et al. Surgical site
    infections in cancer patients with intrathecal drug delivery devices. Pain Med. 2017;18:520 – 525.

  109. Kawata M, Sasabuchi Y, Taketomi S, et al. Atopic dermatitis
    is a novel demographic risk factor for surgical site infection after anterior cruciate ligament reconstruction. Knee Surg Sports Traumatol Arthrosc. 2018;26:3699 – 3705.

  110. Blood AG, Sandoval MF, Burger E, Halverson-Carpenter K. Risk and protective factors associated with surgical infections among spine patients. Surg Infect (Larchmt). 2017;18:234 – 249.
  111. Boster AL, Adair RL, Gooch JL, et al. Best practices for intrathecal Baclofen therapy: dosing and long-term management. Neuromodulation. 2016;19:623 – 631.
  112. Wilkes D. Programmable intrathecal pumps for the management of chronic pain: recommendations for improved efficiency. J Pain Res. 2014;7:571 – 577.
  113. Coffey RJ, Owens ML, Broste SK, et al. Medical practice perspective: identification and mitigation of risk factors for mortality associated with intrathecal opioids for non-cancer pain. Pain Med. 2010;11:1001 – 1009.
  114. Synchromed Programmable Infusion Systems. Clinical Reference Guide. Medtronic; 2021.
  115. Prometra II. Programmable infusion pump system product information. Flowonix. 2017.
  116. Tangen KM, Leval R, Mehta AI, Linninger AA. Computational
    and in vitro experimental investigation of intrathecal drug distribution: parametric study of the effect of injection volume, cerebrospinal fluid pulsatility, and drug uptake. Anesth Analg. 2017;124:1686 – 1696    .

  117. Artru A. Spinal cerebrospinal fluid chemistry and physiology. In: Spinal Drug Delivery. Elsevier;1999:177 – 237.
  118. Kuttler A, Dimke T, Kern S, Helmlinger G, Stanski D, Finelli
    LA. Understanding pharmacokinetics using realistic computational models of fluid dynamics: biosimulation of drug distribution within the CSF space for intrathecal drugs. J Pharmacokinet Pharmacodyn. 2010;37:629 – 644.

  119. Rosen SM, Bromberg TA, Padda G, et al. Intrathecal administration of Infumorph(R) vs compounded morphine for treatment of intractable pain using the Prometra(R) programmable pump. Pain Med. 2013;14:865 – 873.
  120. Hettiarachchi HD, Hsu Y, Harris Jr TJ, Penn R, Linninger AA. The effect of pulsatile flow on intrathecal drug delivery in the spinal canal. Ann Biomed Eng. 2011;39:2592 – 2602.
  121. McDowell G. Use of the personal therapy manager with Prialt (ziconotide intrathecal infusion) for patient controlled analgesia: a case series highlighting techniques and outcomes. Presented at: 14th Annual Meeting of the North American Neuromodulation Society; 2010. Las Vegas, NV.
  122. McDowell 2nd GC, Pope JE. Intrathecal ziconotide: dosing and administration strategies in patients with refractory chronic pain.
    Neuromodulation. 2016;19:522    .

  123. Sindt JE, Odell DW, Tariq R, Presson AP, Zhang C, Brogan SE. Initial intrathecal dose titration and predictors of early dose escalation in patients with cancer using a 100 : 1 oral to intrathecal morphine conversion ratio. Neuromodulation. 2021;24:1157 – 1166.
  124. Hamza M, Doleys D, Wells M, et al. Prospective study of 3-year follow-up of low-dose intrathecal opioids in the management of chronic nonmalignant pain. Pain Med. 2012;13:1304 – 1313.
  125. Ilias W, Todoroff B. Optimizing pain control through the use of implantable Med Devices (Auckl). 2008;1:41 – 47.
  126. Bienfait F, Jubier-Hamon S, Seegers V, et al. First evaluation switching from ropivacaine to highly concentrated bupivacaine in intrathecal mixtures for cancer Neuromodulation. 2021;24:1215 – 1222.
  127. Hayek SM, Veizi E, Hanes M. Intrathecal hydromorphone and bupivacaine combination therapy for post-laminectomy syndrome optimized with patient-activated bolus device. Pain Med. 2016;17:56 1 – 571.
  128. Grider JS, Harned ME, Etscheidt MA. Patient selection and outcomes using a low-dose intrathecal opioid trialing method for chronic nonmalignant pain. Pain Phys. 2011;14:343 – 351.
  129. Grider JS, Etscheidt MA, Harned ME, et al. Trialing and maintenance dosing using a low-dose intrathecal opioid method for chronic nonmalignant pain: a prospective 36-month study.
    Neuromodulation. 2016;19:206 – 219    .

  130. Malheiro L, Gomes A, Barbosa P, Santos L, Sarmento A. Infectious complications of intrathecal drug administration systems for spasticity and chronic pain: 145 patients from a tertiary care center. Neuromodulation. 2015;18:421 – 427.
  131. Farid R. Problem-solving in patients with targeted drug delivery systems. Mo Med. 2017;114:52 – 56.
  132. Sharma K, Marcus JR. Bevacizumab and wound-healing complications: mechanisms of action, clinical evidence, and
    management recommendations for the     plastic surgeon. Ann Plast Surg. 2013;71:434 – 440.

  133. Paice JA, Penn RD, Shott S. Intraspinal morphine for chronic pain: a retrospective, multicenter study. J Pain Symptom
    Manage    . 1996;11:71 – 80    .

  134. Hayek SM, Veizi IE, Narouze SN, Mekhail N. Age-dependent intrathecal opioid escalation in chronic noncancer pain patients. Pain Med. 2011;12:1179 – 1189.
  135. Mekhail N, Mahboobi R, Farajzadeh Deroee A, et al. Factors that might impact intrathecal drug delivery (IDD) dose escalation: a longitudinal study. Pain Pract. 2014;14:301 – 308.
  136. Veizi IE, Hayek SM, Narouze S, Pope JE, Mekhail N. Combination of intrathecal opioids with bupivacaine attenuates opioid dose escalation in chronic noncancer pain patients. Pain Med. 2011;12:1481 – 1489.
  137. De Conno F, Caraceni A, Martini C, Spoldi E, Salvetti M, Ventafridda V. Hyperalgesia and myoclonus with intrathecal infusion of high-dose morphine. Pain. 1991;47:337 – 339.
  138. Singla A, Stojanovic MP, Chen L, Mao J. A differential diagnosis of hyperalgesia, toxicity, and withdrawal from intrathecal morphine infusion. Anesth Analg. 2007;105:1816 – 1819.
  139. Aldrete JA, Couto da Silva JM. Leg edema from intrathecal opiate infusions. Eur J Pain. 2000;4:361 – 365.
  140. Veizi E, Tornero-Bold M, Hayek SM. Resolution of intrathecal hydromorphone or morphine-induced peripheral edema by opioid rotation to fentanyl: a case series. Pain Pract. 2016;16:E94 – E98.
  141. Duarte RV, Raphael JH, Southall JL, Baker C, Ashford RL. Intrathecal granuloma formation as a result of opioid delivery:
    systematic literature review of case     reports and analysis against a control group. Clin Neurol Neurosurg. 2012;114:577– 584.

  142. Kumar K, Kelly M, Pirlot T. Continuous intrathecal morphine treatment for chronic pain of nonmalignant etiology: long-term
    bene    fits and effi Surg Neurol. 2001;55:79–86 [discussion 86].

  143. Wang Y, Mitchell J, Moriyama K, et al. Age-dependent morphine tolerance development in the rat. Anesth Analg. 2005;100:1733 – 1739.
  144. Hassenbusch SJ, Portenoy RK. Current practices in intraspinal therapy–a survey of clinical trends and decision making. J Pain Symptom Manage. 2000;20:S4 – S11.
  145. Staats P, Whitworth M, Barakat M, Anderson W, Lilienfeld S. The use of implanted programmable infusion pumps in the management of nonmalignant, chronic low-back pain. Neuromodulation. 2007;10:376 – 380.
  146. Mironer YE, Haasis JC, Chapple I, Brown C, Satterthwaite JR. Efficacy and safety of intrathecal opioid/bupivacaine mixture in chronic nonmalignant pain: a double blind, randomized, crossover, multicenter study by the National Forum of Independent Pain Clinicians (NFIPC). Neuromodulation. 2002;5:208 – 213.
  147. Deer TR, Caraway DL, Kim CK, Dempsey CD, Stewart CD, McNeil KF. Clinical experience with intrathecal bupivacaine in combination with opioid for the treatment of chronic pain related to failed back surgery syndrome and metastatic cancer pain of the spine. Spine J. 2002;2:274 – 278.
  148. Veizi IE, Hayek SM, Hanes M, Galica R, Katta S, Yaksh T. Primary hydromorphone-related intrathecal catheter tip granulomas: is there a role for dose and concentration? Neuromodulation. 2016;19:760 – 769.
  149. Delhaas EM, Harhangi BS, Frankema SPG, Huygen FJPM, van der Lugt A. Catheter access port (computed tomography) myelography in intrathecal drug delivery troubleshooting: A case series of 70 procedures. Neuromodulation. 2020;23:949.

  150. Natusch D. Equianalgesic doses of opioids – their use in clinical practice. Br J Pain. 2012;6:43 – 46.
  151. Beaver WT, Wallenstein SL, Houde RW, Rogers A. A comparison of the analgesic effects of pentazocine and morphine in patients with cancer. Clin Pharmacol Ther. 1966;7:740 – 751.
  152. McNicol E, Horowicz-Mehler N, Fisk RA, et al. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. J Pain. 2003;4:231 – 256.
  153. Anderson VC, Cooke B, Burchiel KJ. Intrathecal hydromorphone for chronic nonmalignant pain: a retrospective study. Pain Med. 2001;2:287 – 297.
  154. Calculating total daily dose of opioids for safer dosage. Center for Disease Control and Prevention, National Center for Injury Prevention and Control.

  155. Quigley C. Opioid switching to improve pain relief and drug tolerability. Cochrane Database Syst Rev. 2004;2004:CD004847.
  156. Gammaitoni AR, Fine P, Alvarez N, McPherson ML, Bergmark S. Clinical application of opioid equianalgesic data. Clin J Pain. 2003;19:286 – 297.
  157. Brant JM. Opioid equianalgesic conversion: the right dose. Clin J Oncol Nurs. 2001;5:163 – 165.
  158. Knotkova H, Fine PG, Portenoy RK. Opioid rotation: the science and the limitations of the equianalgesic dose table. J Pain Symptom Manage. 2009;38:426 – 439.
  159. Waara-Wolleat KL, Hildebrand KR, Stewart GR. A review of intrathecal fentanyl and sufentanil for the treatment of chronic pain. Pain Med. 2006;7:251 – 259.
  160. Mercadante S. Opioid rotation for cancer pain: rationale and clinical aspects. Cancer. 1999;86:1856 – 1866.
  161. Indelicato RA, Portenoy RK. Opioid rotation in the management of refractory cancer pain. J Clin Oncol. 2003;21:87s – 91s.
  162. Fine PG, Portenoy RK. Establishing “best practices” for opioid rotation: conclusions of an expert panel. J Pain Symptom Manage. 2009;38:418 – 425.
  163. Sharan AD, Riley J, Falowski S, et al. Association of opioid usage with spinal cord stimulation outcomes. Pain Med. 2018;19:699 – 707.
  164. Hatheway JA, Bansal M, Nichols-Ricker CI. Systemic opioid reduction and discontinuation following implantation of
    intrathecal drug-delivery systems for     chronic pain: a retrospective cohort analysis. Neuromodulation. 2020;23:961 – 969.

  165. Fraifeld EM, Hatheway JA, Ricker CN. Systemic opioid prescribing patterns and total cost of care in patients initiating spinal cord stimulation therapy: a retrospective analysis. Pain Med. 2021;22:784 – 799.
  166. FDA Approved Drug Products. Silver Spring, MD: U.S. Food and Drug Administration; 2006. Accessed August 17, 2020.
  167. Wermeling D, Drass M, Ellis D, et al. Pharmacokinetics and pharmacodynamics of intrathecal ziconotide in chronic pain
    patients. J Clin Pharmacol. 2003;43:624 – 636    .

  168. Yaksh TL, de Kater A, Dean R, Best BM, Miljanich GP. Pharmacokinetic analysis of ziconotide (SNX-111), an
    intrathecal N-type calcium channel blocking analgesic, delivered by bolus and infusion in the dog. Neuromodulation. 2012;15(6):508    .

  169. Sirianni RW, Zheng MQ, Saltzman WM, Huang Y, Carson RE. Direct, quantitative, and noninvasive imaging of the transport of active agents through intact brain with positron emission tomography. Mol Imaging Biol. 2013;15:596 – 605.
  170. Maeyaert J, Buchser E, Van Buyten JP, Rainov NG, Becker R. Patient-controlled analgesia in intrathecal therapy for chronic pain: safety and effective operation of the model 8831 Personal Therapy Manager with a pre-implanted SynchroMed Infusion System. Neuromodulation. 2003;6:133 – 141.
  171. Saulino M, Kim PS, Shaw E. Practical considerations and patient selection for intrathecal drug delivery in the management
    of chronic pain. J Pain Res.     2014;7:627 – 638.

  172. Deer T, Hagedorn JM. How has ziconotide impacted non-cancer pain management? Expert Opin Pharmacother. 2020;21:507 – 511.
  173. Wang YX, Gao D, Pettus M, Phillips C, Bowersox SS. Interactions of intrathecally administered ziconotide, a selective blocker of neuronal N-type voltage-sensitive calcium channels, with morphine on nociception in rats. Pain. 2000;84:271 – 281.
  174. Alicino I, Giglio M, Manca F, Bruno F, Puntillo F. Intrathecal combination of ziconotide and morphine for refractory cancer pain: a rapidly acting and effective Pain. 2012;153:245 – 249.
  175. Highlights of prescribing information for prialt TerSera Therapeutics.

  176. Smith HS, Deer TR. Safety and efficacy of intrathecal ziconotide in the management of severe chronic pain. Ther Clin Risk Manag. 2009;5:521 – 534.
  177. Brogan SE, Winter NB, Okifuji A. Prospective observational study of patient-controlled intrathecal analgesia: impact on cancer-associated symptoms, breakthrough pain control, and patient satisfaction. Reg Anesth Pain Med. 2015;40:369 – 375.
  178. Brogan SE, Winter NB. Patient-controlled intrathecal analgesia for the management of breakthrough cancer pain: a retrospective review and commentary. Pain Med. 2011;12:1758 – 1768.
  179. Rigoli G, Terrini G, Cordioli Z. Intrathecal Baclofen withdrawal syndrome caused by low residual volume in the pump reservoir: a report of 2 cases. Arch Phys Med Rehabil. 2004;85:2064 – 2066.
  180. Elovic E, Kirshblum SC. Managing spasticity in spinal cord injury: safe administration of bridge boluses during intrathecal Baclofen pump refi J Spinal Cord Med. 2003;26:2 – 4.
  181. Ward M, Mammis A, Barry MT, Heary RF. Novel association between intrathecal drug administration and arachnoiditis ossifi World Neurosurg. 2018;115:400 – 406.
  182. Coyne PJ, Hansen LA, Laird J, Buster P, Smith TJ. Massive hydromorphone dose delivered subcutaneously instead of intrathecally: guidelines for prevention and management of opioid, local anesthetic, and clonidine overdose. J Pain Symptom Manage. 2004;28:273 – 276.

  183. Hurdle MF, Locketz AJ, Smith J. A technique for ultrasound-guided intrathecal drug-delivery system refi Am J Phys Med Rehabil. 2007;86:250 – 251.
  184. Abd-Elsayed A. Pocket fill during intrathecal pump refill: is it a frequent occurrence? Neuromodulation. 2019;22:761.
  185. Maino P, Perez RSGM, Koetsier E. Intrathecal pump refills, pocket fills, and symptoms of drug overdose: a prospective, observational study comparing the injected drug volume vs. the drug volume effectively measured inside the pump. Neuromodulation. 2017;20:733 – 739.
  186. Matthys C, Jacobs M, Rossat J, Perruchoud C. Accuracy of template versus ultrasound identification of the reservoir access port of intrathecal drug delivery Neuromodulation. 2020;23:944 – 948.
  187. Singa RM, Buvanendran A, McCarthy RJ. A comparison of refill procedures and patient outcomes following ultrasound-guided and template-guided intrathecal drug delivery systems with recessed ports. Neuromodulation. 2020;23:938 – 943.
  188. Miracle AC, Fox MA, Ayyangar RN, Vyas A, Mukherji SK, Quint DJ. Imaging evaluation of intrathecal Baclofen pump-catheter systems. AJNR Am J Neuroradiol. 2011;32:1158 – 1164.

  189. Delhaas E, Harhangi B, Frankema S, Huygen F, van der Lugt A. Catheter access port (computed tomography) myelography in intrathecal drug delivery troubleshooting: a case series of 70 procedures. Neuromodulation. 2020;23:949 – 960.
  190. Lew SM, Psaty EL, Abbott R. An unusual cause of overdose after Baclofen pump implantation: case report. Neurosurgery. 2005;56:E624 [discussion: E624].
  191. Ellis JA, Leung R, Winfree CJ. Spinal infusion pump-catheter leak detected by high-resolution 3D computed tomography. J Neurosurg Spine. 2011;15:555 – 557.
  192. Dupoiron D, Carvajal G. High-resolution three-dimensional computed tomography reconstruction as first-line imaging modality to detect intrathecal catheter Neuromodulation. 2018;21:717 – 720.
  193. Hagedorn JM, Bendel MA, Moeschler SM, Lamer TJ, Pope JE, Deer TR. Intrathecal gadolinium use for the chronic pain physician. Neuromodulation. 2019;22:769 – 774.
  194. Nagel SJ, Reddy CG, Frizon LA, et al. Intrathecal therapeutics: device design, access methods, and complication mitigation. Neuromodulation. 2018;21:625.

  195. Galica R, Hayek SM, Veizi IE, Lawrence MM, Khalil AA, McEwan MT. Sudden intrathecal drug delivery device motor stalls: a case series. Reg Anesth Pain Med. 2016;41:135 – 139.
  196. Goel V, Yang Y, Kanwar S, et al. Adverse events and complications associated with intrathecal drug delivery systems: insights from the Manufacturer and User Facility Device Experience (MAUDE) database.
    Neuromodulation. 2021;24:1181.

  197. Kosturakis A, Gebhardt R. SynchroMed II intrathecal pump memory errors due to repeated magnetic resonance imaging. Pain Phys. 2012;15:475 – 4 77.
  198. Wesemann K, Coffey RJ, Wallace MS, Tan Y, Broste S, Buvanendran A. Clinical accuracy and safety using the Synchromed II intrathecal drug infusion pump. Reg Anesth Pain Med. 2014;39:341 – 346.
  199. Farid R, Binz K, Emerson JA, Murdock F. Accuracy and precision of the SynchroMed II Pump. Neuromodulation. 2019;22:805 – 810.
  200. Rauck R, Deer T, Rosen S, et al. Long-term follow-up of a novel implantable programmable infusion pump. Neuromodulation. 2013;16:163 – 167.
  201. Skalsky AJ, Dalal P, Le J, Ewing E, Yaszay B. Screening intrathecal Baclofen pump systems for catheter patency via catheter access port aspiration. Neuromodulation. 2020;23:1003 – 1008.
  202. Dvorak EM, McGuire JR, Nelson ME. Incidence and identification of intrathecal Baclofen catheter malfunction. PM R. 2010;2:751 – 756.
  203. Delhaas EM, van der Lugt A. Low-dose computed tomography with two- and three-dimensional postprocessing as an alternative to plain radiography for intrathecal catheter visualization: a phantom pilot study. Neuromodulation. 2019;22:818 – 822.
  204. Motta F, Antonello CE. Analysis of complications in 430 consecutive pediatric patients treated with intrathecal Baclofen therapy: 14-year experience. J Neurosurg Pediatr. 2014;13:301 – 306.
  205. Shao J, Frizon L, Machado A, et al. Occlusion of the Ascenda
    catheter in a patient with pump twiddlers’s syndrome: a case report. Anesth Pain Med. 2018;8(2), e65312.

  206. Saulino M, Anderson DJ, Doble J, et al. Best practices for intrathecal Baclofen therapy: troubleshooting. Neuromodulation. 2016;19:632–641.
  207. Frémondière F, Lacoeuille F, Sher A, et al. Assessment of intrathecal Baclofen pump malfunction: a new algorithm including nuclear medicine investigation. Ann Phys Rehabil Med. 2016;59:e140 – e141.
  208. Morgalla M, Fortunato M, Azam A, Tatagiba M, Lepski G. High-resolution three-dimensional computed tomography for assessing complications related to intrathecal drug delivery. Pain Phys. 2016;19:E775 – E780.
  209. Saulino M, Turner M, Miesel K, et al. Can cerebrospinal fluid pressure detect catheter complications in patients who experience loss of effectiveness with intrathecal Baclofen therapy? Neuromodulation. 2017;20:187 – 197.
  210. Delhaas EM, van Assema DME, Fröberg AC, et al. Isotopic scintigraphy in intrathecal drug delivery failure: a single-institution case series. Neuromodulation. 2021;24:1190 – 1198.

  211. Yowtak J, Cato K, Williams H, et al. Indium 111 diethylenetriamine pentaacetic acid scintigraphy in the identification and management of intrathecal pump PM & R. 2013;5:32 – 38.
  212. Maus TP, Schueler BA, Magnuson DJ, Magnuson D. Relative conspicuity of gadolinium-based contrast agents in
    interventional pain procedures. Pain Med.     2017;18:651 – 654.

  213. Safriel Y, Ali M, Hayt M, Ang R. Gadolinium use in spine procedures for patients with allergy to iodinated contrast-experience of 127 procedures. AJNR Am J Neuroradiol. 2006;27:1194 – 1197.
  214. Akbar JJ, Luetmer PH, Schwartz KM, Hunt CH, Diehn FE, Eckel LJ. The role of MR myelography with intrathecal gadolinium in localization of spinal CSF leaks in patients with spontaneous intracranial hypotension. AJNR Am J Neuroradiol. 2012;33:535 – 540.
  215. Provenzano DA, Pellis Z, DeRiggi L. Fatal gadolinium-induced encephalopathy following accidental intrathecal administration: a case report and a comprehensive evidence-based review. Reg Anesth Pain Med. 2019;44:721 – 729.
  216. Maus T. Intrathecal gadolinium: a fatal flaw. Reg Anesth Pain Med. 2019;44:687 – 688.
  217. Staats PS. Complications of intrathecal therapy. Pain Med. 2008;9:S102 – S107.
  218. Johnson ML, Visser EJ, Goucke CR. Massive clonidine overdose during refill of an implanted drug delivery device for intrathecal analgesia: a review of inadvertent soft-tissue injection during implantable drug delivery device refills and its man Pain Med. 2011;12:1032 – 1040.
  219. Perruchoud C, Bovy M, Rutschmann B, Durrer A, Buchser E. Silicone septum leakage at the origin of a drug overdose in a patient implanted with an intrathecal pump. Neuromodulation. 2013;16:467, 63 [discussion: 469].
  220. Gofeld M, McQueen CK. Ultrasound-guided intrathecal pump access and prevention of the pocket. Pain Med. 2011;12:607 – 611.
  221. Saulino M, Gofeld M. “Sonology” of programmable intrathecal pumps. Neuromodulation. 2014;17:696 – 698 [discussion: 698].
  222. Maneyapanda MB, Chang Chien GC, Mattie R, Amorapanth P, Reger C, McCormick ZL. Ultrasound guidance for technically challenging intrathecal Baclofen pump refill: Three Cases and Procedure Description. Am J Phys Med Rehabil. 2016;95:692 – 697.
  223. Maino P, Koetsier E, Perez RS. The accuracy of template-guided refill technique of intrathecal pumps controlled by fluoroscopy: an observational study. Neuromodulation. 2015;18:428 – 432.
  224. Maino P, van Kuijk SMJ, Perez RSGM, Koetsier E. Ease of fill port access during the ultrasound-guided vs. the blind refill technique of intrathecal drug delivery systems with a raised septum, a prospective comparison study. Neuromodulation. 2018;21:641 – 647.
  225. Maino P, van Kuijk SMJ, Perez RSGM, Koetsier E. Refill procedures of intrathecal drug delivery systems with a recessed fill port on the pump surface: a prospective comparison study of ultrasound-guided vs. blind refill technique. Neuromodulation. 2019;22:799 – 804.
  226. Johns MW. Reliability and factor analysis of the Epworth Sleepiness Scale. Sleep. 1992;15:376 – 381.
  227. Nagappa M, Liao P, Wong J, et al. Validation of the STOP-Bang Questionnaire as a screening tool for obstructive sleep apnea among different populations: a systematic review and meta-analysis. PLOS ONE. 2015;10, e0143697.
  228. Dronge AS, Perkal MF, Kancir S, Concato J, Aslan M, Rosenthal RA. Long-term glycemic control and postoperative infectious complications. Arch Surg. 2006;141:375 – 380 [discussion: 380].
  229. Zerr KJ, Furnary AP, Grunkemeier GL, Bookin S, Kanhere V, Starr A. Glucose control lowers the risk of wound infection in diabetics after open heart operations. Ann Thorac Surg. 1997;63:356–361.
  230. Buist AS, Sexton GJ, Nagy JM, Ross BB. The effect of smoking cessation and modification on lung function. Am Rev Respir Dis. 1976;114:115 – 122.
  231. Kinsella JB, Rassekh CH, Wassmuth ZD, Hokanson JA, Calhoun KH. Smoking increases facial skin flap complications. Ann Otol Rhinol Laryngol. 1999;108:139 – 142.
  232. Schipmann S, Akalin E, Doods J, Ewelt C, Stummer W, Suero Molina E. When the infection hits the wound: matched case-control study in a neurosurgical patient collective including systematic literature review and risk factors analysis. World Neurosurg. 2016;95:178 – 189.
  233. Wyles CC, Hevesi M, Osmon DR, et al. John Charnley Award: increased risk of prosthetic joint infection following primary total knee and hip arthroplasty with the use of alternative antibiotics to cefazolin. Bone Joint J. 2019;101:9 – 15.
  234. Blumenthal KG, Ryan EE, Li Y, Lee H, Kuhlen JL, Shenoy ES. The impact of a reported penicillin allergy on surgical site
    infection risk. Clin Infect Dis.     2018;66:329 – 336.

  235. Henderson JM, Levy RM, Bedder MD, et al. NANS training requirements for spinal cord stimulation devices: selection, implantation, and follow-up. Neuromodulation. 2009;12:171 – 174.
  236. Bratzler DW, Houck PM, et al, Surgical Infection Prevention Guidelines Writers Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. Clin Infect Dis. 2004;38:1706 – 1715.
  237. Alexander JW, Solomkin JS, Edwards MJ. Updated recommendations for control of surgical site infections. Ann Surg. 2011;253:1082 – 1093.
  238. Bratzler DW, Dellinger EP, Olsen KM, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Surg Infect (Larchmt). 2013;14:73 – 156.
  239. Nadherny W, Anderson B, Abd-Elsayed A. Perioperative and periprocedural care of patients with intrathecal pump therapy. Neuromodulation. October;22:775.

  240. Magill ST, Wang P, Eller JL, Burchiel KJ. Differentiating intrathecal catheter tip granulomas from normal magnetic resonance image distortion caused by metallic catheter tips. Neurosurgery. 2008;62(1):242 – 248.
  241. Schultz DM, Abd-Elsayed A, Calodney A, Stromberg K, Weaver T, Spencer RJ. Targeted drug delivery for chronic nonmalignant pain: longitudinal data from the Product Surveillance Registry. Neuromodulation. 2021;24:1167 – 1175.
  242. Narouze S, Benzon HT, Provenzano DA, et al. Interventional spine and pain procedures in patients on antiplatelet and anticoagulant medications: guidelines from the American Society of Regional Anesthesia and Pain Medicine, the European Society of Regional Anaesthesia and Pain Therapy, the American Academy of Pain Medicine, the International Neuromodulation Society, the North American Neuromodulation Society, and the World Institute of Pain. Reg Anesth Pain Med. 2015;40:182 – 212.
  243. Petraglia FW, Farber SH, Gramer R, et al. The incidence of spinal cord injury in implantation of percutaneous and paddle electrodes for spinal cord stimulation. Neuromodulation. 2016;19:85 – 90.
  244. Mendoza PA, Narula S, McIntyre WF, et al. Continued versus interrupted direct oral anticoagulation for cardiac electronic device implantation: a systematic Pacing Clin Electrophysiol. 2020;43:1373 – 1381.
  245. Birnie D, Healey JS, Krahn A, et al. Bridge or continue coumadin for device surgery: a randomized controlled trial rationale and design. Curr Opin Cardiol. 2009;24:82 – 87.

  246. Delhaas EM, Beersen N, Redekop WK, Klazinga NS. Long-term outcomes of continuous intrathecal Baclofen infusion for treatment of spasticity: a prospective multicenter follow-up study. Neuromodulation. 2008;11:227 – 236.
  247. Stetkarova I, Yablon SA, Kofler M, Stokic DS. Procedure – and device-related complications of intrathecal Baclofen administration for management of adult muscle hypertonia: a review. Neurorehabil Neural Repair. 2010;24:609–619.
  248. Awaad Y, Rizk T, Siddiqui I, Roosen N, McIntosh K, Waines GM. Complications of intrathecal Baclofen pump: prevention and cure. ISRN Neurol. 2012;2012, 575168.
  249. Delhaas EM, Huygen FJPM. Complications associated with intrathecal drug delivery systems. BJA Educ. 2020;20:51 – 57.

  250. Kamran S, Wright BD. Complications of intrathecal drug delivery systems. Neuromodulation. 2001;4:111 – 115.

  251. Stearns LM, Abd-Elsayed A, Perruchoud C, et al. Intrathecal drug delivery systems for cancer pain: an analysis of a prospective, multicenter product surveillance registry. Anesth Analg. 2020;130:289 – 297.

  252. Motta F, Antonello CE. Comparison between an Ascenda and a silicone catheter in intrathecal Baclofen therapy in pediatric patients: analysis of complications. J Neurosurg Pediatr. 2016;18:493 – 498.
  253. Bayliss CE, Beanlands DS, Baird RJ. The pacemaker-twiddler’s syndrome: a new complication of implantable transvenous pacemakers. Can Med Assoc J. 1968;99:371 – 373.
  254. Moens M, De Smedt A, Brouns R. Opioid withdrawal due to Twiddler syndrome.
  255. Yaksh TL, Eddinger KA, Kokubu S, et al. Mast cell degranulation and fibroblast activation in the morphine-induced spinal mass: role of mas-related G protein-coupled receptor signaling. Anesthesiology. 2019;131:132–147.

  256. Frizon LA, Sabharwal NC, Maiti T, et al. Removal of intrathecal catheters used in drug delivery systems. Neuromodulation. 2018;21:665 – 668.

  257. Stearns LJ, Narang S, Albright Jr RE, et al. Assessment of health care utilization and cost of targeted drug delivery and conventional medical management vs conventional medical management alone for patients with cancer-related pain. JAMA Netw Open. 2019;2, e191549.
  258. Stearns LJ, Hinnenthal JA, Hammond K, Berryman E, Janjan NA. Health services utilization and payments in patients with cancer pain: a comparison of intrathecal drug delivery vs. conventional medical management. Neuromodulation. 2016;19:196 – 205.
  259. Brogan SE, Winter NB, Abiodun A, Safarpour R. A cost utilization analysis of intrathecal therapy for refractory cancer pain: identifying factors associated with cost benefi Pain Med. 2013;14:478 – 486.
  260. Health Quality Ontario. Intrathecal drug delivery systems for cancer pain: a health technology assessment. Ont Health Technol Assess Ser. 2016;16:1 – 51.
  261. Kumar K, Hunter G, Demeria DD. Treatment of chronic pain by using intrathecal drug therapy compared with conventional pain therapies: a cost-effectiveness J Neurosurg. 2002;97:803 – 810.
  262. Kumar K, Rizvi S, Bishop S. Cost effectiveness of intrathecal drug therapy in management of chronic nonmalignant pain. Clin J Pain. 2013;29:138 – 145.
  263. Biggs SA, Duarte RV, Raphael JH, Ashford RL. Influence of a latent period in QALY analysis: pilot study of intrathecal drug delivery systems for chronic non-malignant pain. Br J Neurosurg. 2011;25:401 – 406.
  264. Dewilde S, Verdian L, Maclaine GD. Cost-effectiveness of ziconotide in intrathecal pain management for severe chronic pain patients in the UK. Curr Med Res Opin. 2009;25:2007 – 2019.
  265. de Lissovoy G, Matza LS, Green H, Werner M, Edgar T. Cost-effectiveness of intrathecal Baclofen therapy for the treatment of severe spasticity associated with cerebral palsy. J Child Neurol. 2007;22:49 – 59.
  266. Hoving MA, Evers SM, Ament AJ, van Raak EP, Vles JS. Intrathecal Baclofen therapy in children with intractable spastic cerebral palsy: a cost-effectiveness Dev Med Child Neurol. 2008;50:450 – 455.
  267. Saulino M, Guillemette S, Leier J, Hinnenthal J. Medical cost impact of intrathecal Baclofen therapy for severe spasticity. Neuromodulation. 2015;18:141–149 [discussion: 149].
  268. Duarte RV, Lambe T, Raphael JH, Eldabe S, Andronis L. Intrathecal drug delivery systems for the management of chronic noncancer pain: a systematic review of economic evaluations. Pain Pract. 2018;18:666–686.
  269. Fang H, Frean M, Sylwestrzak G, Ukert B. Trends in disenrollment and reenrollment within US commercial health insurance plans, 2006–2018. JAMA Netw Open. 2022;5, e220320.
  270. Ramsey SD, Willke RJ, Glick H, et al. Cost-effectiveness analysis alongside clinical trials II-An ISPOR Good Research Practices Task Force report. Value Health. 2015;18:161–172.
  271. Petrou S, Gray A. Economic evaluation alongside randomized controlled trials: design, conduct, analysis, and reporting.
    BMJ. 2011;342, d1548    .

  272. Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care
    Programmes    . 4th ed. Oxford University     Press; 2015.

  273. Glick HA, Doshi JA, Sonnad SS, Polsky D. Economic Evaluation in Clinical Trials. 2nd Oxford University Press; 2015.

More effective management of intrathecal drug delivery.

© Copyright 2025. All rights reserved.

More effective management of intrathecal drug delivery devices.

© Copyright 2025. All rights reserved.

More effective management of intrathecal drug delivery devices.

© Copyright 2025. All rights reserved.